Fusion protein of relaxin or analogue and medical application thereof
Patent Information
- Application Number
- CN202380032234.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-07
- Filing Date
- 2023-05-05
- Publication Date
- 2024-11-26
AI Technical Summary
The short half-life of relaxin results in its short-lived efficacy in clinical applications. Existing recombinant relaxin requires continuous intravenous infusion, which is inconvenient and costly for patients, and it is difficult to effectively prolong its stability in the body with existing technology.
A fusion protein containing a serum albumin-binding molecule was designed. By combining with relaxin or its analogues, the long half-life properties of albumin can be used to extend the half-life of the drug in plasma and improve the stability and activity of the drug. The binding molecule contains a single variable domain of immunoglobulin, has high affinity to bind to serum albumin, and prolongs its existence time in the body.
It significantly increases the half-life of relaxin or its analogues in the body, enhances the stability and clinical application potential of the drug, reduces the frequency and cost of treatment, and provides a more convenient treatment plan.
Smart Images

Figure 00000049_0000 
Figure 00000049_0001 
Figure 00000050_0000
Abstract
Description
Fusion protein of relaxin or analogues and its medical use
[0001] This disclosure claims priority to the Chinese patent application (application number CN202210491720.7) filed on May 7, 2022. Technical Field
[0002] The present disclosure belongs to the field of biopharmaceuticals and, more specifically, relates to a fusion protein comprising relaxin or an analog thereof and a serum albumin binding domain, and its medical use for treating diseases (e.g., heart failure). Furthermore, the present disclosure relates to a serum albumin binding molecule comprising an immunoglobulin single variable domain (e.g., VHH) capable of binding to serum albumin, exhibiting good plasma stability and useful for extending the plasma half-life of a drug. Background Art
[0003] Relaxin, a crucial hormone during pregnancy, was first discovered by Frederick Hisaw in 1926. It is a polypeptide hormone belonging to the insulin superfamily. In humans, relaxin comprises seven polypeptide members: relaxin 1 (RLN-1 or H1), relaxin 2 (RLN-2 or H2), and relaxin 3 (RLN-3 or H3). These relaxins share low primary sequence homology but similar tertiary structures. Relaxin 2 is the predominant relaxin in human circulation and is encoded by the RLN2 gene. Relaxin is expressed as a prohormone (with the A and B chains linearly linked by a C-peptide). Endoenzymatic hydrolysis removes the C-peptide in vivo, releasing mature relaxin. Natural mature relaxin 2 consists of two polypeptide chains, A and B, covalently linked by two interchain disulfide bonds to form a heterodimer. Chain A also contains a pair of internal disulfide bonds (Schwabe et al. Science 1977, 197, 914-915).
[0004] Relaxin 2 is a pleiotropic hormone whose signaling is primarily mediated through its receptor, RXFP1 (also known as LGR7). RXFP1 is a G protein-coupled receptor (GPCR) rich in leucine repeats. RXFP2 (also known as LGR8) also binds to relaxin 2. Relaxin 2 binding to its receptor activates multiple signaling cascades, including activation of the cAMP and phosphoinositide 3-kinase pathways and the nitric oxide signaling pathway. Relaxin 2 receptor binding also inhibits the phosphorylation of Smad2 / 3, thereby inhibiting the production of extracellular matrix and collagen. Studies have shown that relaxin 2 has physiological effects such as promoting vasodilation, anti-inflammation, reducing vascular resistance and increasing arterial compliance, promoting angiogenesis and remodeling, regulating the extracellular matrix, and combating fibrosis. It has beneficial effects on heart failure and myocardial fibrosis (Chiara Sassoli, et al. Current Molecular Medicine 2022, 22, 196-208).
[0005] The half-life of relaxin 2 (t 1 / 2 ) is very short, and the half-life (t1 / 2) of natural relaxin 2 in the body is only a few minutes, which poses a challenge to relaxin as a therapeutic drug. The natural recombinant relaxin 2 (serelaxin) that has been launched on the market needs to be treated by continuous intravenous infusion in clinical practice, which causes inconvenience to patients and also shows short-term efficacy. Researchers have modified relaxin 2 to increase its half-life (t 1 / 2 ), such as introducing PEG, fatty acid chains, etc. by chemical coupling, or fusing half-life-extending proteins, polypeptides, or Fc by recombinant methods.
[0006] Albumin is the most abundant protein in plasma, accounting for 40-60% of plasma proteins. Albumin can bind to many endogenous and exogenous ligands and is a natural "multifunctional carrier" in the body. Albumin is similar to immunoglobulin G (IgG) and has a relatively long retention time in the body. It has been reported that the half-life of albumin in the human body is about 19-21 days (Berson, SA et al, J. Clin. Invest. 1953, 32, 746-768). This is mainly because: the molecular weight of albumin is 66.5KD, and its molecular hydrodynamic radius exceeds the threshold of glomerular filtration of 3.5-6nm (Lin, JH Curr. Drug Metab. 2009, 10, 661-691); albumin can bind to FcRn, and this binding is pH-dependent. After being internalized into endosomes, the two bind strongly at the acidic pH of the endosomal body (pH 5.5 or 6.0), thereby protecting albumin from lysosomal degradation. As FcRn is transported to the cell surface, under neutral physiological pH conditions, albumin dissociates from FcRn, thereby achieving recycling. This principle is similar to the recycling of IgG, and albumin and IgG bind to two independent sites on FcRn respectively, without affecting each other.
[0007] The present disclosure provides novel single-domain antibodies that bind to serum albumin and can significantly increase the in vivo half-life of active pharmaceutical ingredients. For example, when the serum albumin-binding single-domain antibodies of the present disclosure are fused with relaxin or its analog as an active ingredient to form a fusion protein, the in vivo half-life of relaxin or its analog can be significantly increased. The fusion proteins provided by the present disclosure have high activity, high stability, are easy to produce, and have excellent potential for clinical application.
[0008] Summary of the Invention
[0009] The present disclosure provides a serum albumin binding molecule, which comprises an immunoglobulin single variable domain that specifically binds to serum albumin, has good plasma stability, and can be used to prolong the plasma half-life of a drug.
[0010] serum albumin binding molecules
[0011] The present disclosure provides serum albumin binding molecules.
[0012] In some embodiments, the serum albumin binding molecule comprises an immunoglobulin single variable domain comprising the CDR1, CDR2, and CDR3 of any one of 1) to 5) below:
[0013] 1) CDR1, CDR2, and CDR3 in the amino acid sequence of any one of SEQ ID NOs: 6 and 18-27;
[0014] 2) CDR1, CDR2, and CDR3 in the amino acid sequence of SEQ ID NO: 7;
[0015] 3) CDR1, CDR2, and CDR3 as shown in SEQ ID NOs: 8, 9, and 10, respectively;
[0016] 4) CDR1, CDR2, and CDR3 as shown in SEQ ID NOs: 11, 12, and 13, respectively;
[0017] 5) CDR1 is X1SCX2G (SEQ ID NO: 64), wherein X1 is T or N, and X2 is M or L;
[0018] CDR2 is X3IYX4VGGSTFYX5X6SVKG (SEQ ID NO: 58), wherein X3 is S or T, X4 is T or M, X5 is T or A, and X6 is N or D;
[0019] CDR3 is GSPARCX7X8RDPTTFX9Y (SEQ ID NO: 59), wherein X7 is R or L, X8 is L or R, and X9 is D or N;
[0020] Wherein, one or more of the above X1 to X9 may be conservative amino acid mutations of their optional amino acids.
[0021] The above CDRs are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering systems, for example, the CDRs are defined according to the Kabat numbering system.
[0022] In some embodiments, the serum albumin binding molecule comprises an immunoglobulin single variable domain comprising any one or a combination of any several (eg, 2 or 3) of the CDR1, CDR2, and CDR3 in 1) to 5) above.
[0023] In some embodiments, the serum albumin binding molecule comprises an immunoglobulin single variable domain comprising a CDR1 having 0, 1, 2, 3, 4, or 5 amino acid mutations compared to any of the aforementioned CDR1s; and / or, the immunoglobulin single variable domain comprises a CDR2 having 0, 1, 2, 3, 4, or 5 amino acid mutations compared to any of the aforementioned CDR2s; and / or, the immunoglobulin single variable domain comprises a CDR3 having 0, 1, 2, 3, 4, or 5 amino acid mutations compared to any of the aforementioned CDR3s. In some specific embodiments, the amino acid mutations in CDR1, CDR2, and / or CDR3 are conservative substitutions.
[0024] In some embodiments, the aforementioned immunoglobulin single variable domain is of camelid origin.
[0025] In some embodiments, the immunoglobulin single variable domain is modified by any of the following: humanization, affinity maturation, removal of T cell epitopes, reduction of antibody deamidation, reduction of antibody aggregation, reduction of antibody isomerization, or a combination thereof.
[0026] In some embodiments, the framework regions in the aforementioned humanized immunoglobulin single variable domain are derived from the human heavy chain variable region germline gene IGHV3-23 or IGVH3-66.
[0027] In some specific embodiments, the aforementioned humanized immunoglobulin single variable domain comprises an amino acid mutation at at least one of the following positions: positions 20, 23, 27, 29, 30, 37, 44, 45, 47, 49, 74, 78, 83, and 84 (positions based on the EU numbering system);
[0028] For example, comprising at least one amino acid mutation selected from the group consisting of 20V, 23V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 49A, 74A, 78V, 83Q, or 84P;
[0029] For example, comprising a combination of amino acid mutations selected from any of the following:
[0030] F27N, F29Y, S30L, V37F, G44E, L45R, W47G;
[0031] L20V, F27N, F29Y, S30L, V37F, G44E, L45R, W47G;
[0032] A23V, F27N, F29Y, S30L, V37F, G44E, L45R, W47G;
[0033] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, S74A;
[0034] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, L78V;
[0035] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, S49A;
[0036] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, R83Q, A84P;
[0037] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, A84P;
[0038] S30L, V37F, G44E, L45R, W47G, A84P; or
[0039] S30L, V37F, G44E, L45R, W47G.
[0040] In some embodiments, the serum albumin binding molecules provided herein comprise an immunoglobulin single variable domain comprising or being any one of SEQ ID NO: 6 or 7, or an amino acid sequence having at least 80% or at least 90% sequence identity thereto. In some embodiments, the immunoglobulin single variable domain is of camelid origin.
[0041] In some embodiments, the serum albumin binding molecules provided herein comprise an immunoglobulin single variable domain comprising or being set forth in any one of SEQ ID NOs: 18-27, or an amino acid sequence having at least 80% or at least 90% sequence identity thereto. In some embodiments, the immunoglobulin single variable domain is humanized.
[0042] In the present disclosure, "at least 90% (sequence) identity" encompasses at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% (sequence) identity; "at least 80% (sequence) identity" encompasses at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% (sequence) identity, and ranges between any two of the foregoing values, including integers and decimals.
[0043] In some embodiments, the immunoglobulin single variable domain in the serum albumin binding molecules provided by the present disclosure comprises three complementarity determining regions CDR1, CDR2 and CDR3 and four FRs, arranged from amino terminus to carboxyl terminus in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0044] In some embodiments, the serum albumin binding molecules provided by the present disclosure are antibodies or antigen-binding fragments thereof that bind to serum albumin, or conjugates or fusion proteins comprising the antibodies or antigen-binding fragments thereof.
[0045] In some embodiments, the aforementioned antibody is a camel antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.
[0046] In some embodiments, the aforementioned antigen-binding fragment is an sdAb, a bispecific antibody, or a multispecific antibody.
[0047] In some embodiments, the aforementioned immunoglobulin single variable domain is VHH.
[0048] In some embodiments, the aforementioned immunoglobulin single variable domain is a humanized VHH.
[0049] In some embodiments, the aforementioned immunoglobulin single variable domain is an affinity-matured VHH.
[0050] In some embodiments, a serum albumin binding molecule is provided, which comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8) the aforementioned immunoglobulin single variable domains. The immunoglobulin single variable domains can be the same or different, and any two immunoglobulin single variable domains can be directly connected or connected through a linker.
[0051] In some embodiments, serum albumin binding molecules are provided that bind to or compete for binding to the same epitope as the aforementioned immunoglobulin single variable domains of the present disclosure.
[0052] In some embodiments, serum albumin binding molecules are provided that block the binding of the aforementioned immunoglobulin single variable domains of the present disclosure to serum albumin.
[0053] In some embodiments, serum albumin binding molecules are provided, the binding of which to serum albumin is blocked by the immunoglobulin single variable domains disclosed above.
[0054] In some embodiments, the serum albumin binding molecules provided by the present disclosure further comprise an immunoglobulin Fc region, such as an Fc region selected from human IgG1, IgG2, IgG3, and IgG4; or a histidine tag, such as a (His)6 tag or a (His)8 tag.
[0055] Fc regions useful in the present disclosure can be derived from immunoglobulins of different subtypes, such as IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM. In some embodiments, the Fc region includes the hinge region or part of the hinge region, CH2 region, and CH3 region of the constant region.
[0056] In some embodiments, the aforementioned immunoglobulin single variable domain and the Fc region or histidine tag may be connected by a linker. The linker can be a non-functional amino acid sequence with a length of 1-20 or more amino acids and no secondary or higher structure. For example, the linker is a flexible linker, such as G4S (SEQ ID NO: 67), GS, GAP, (G4S)2 (SEQ ID NO: 68), (G4S)3 (SEQ ID NO: 69), (G4S)4 (SEQ ID NO: 70), (G4S)5 (SEQ ID NO: 71), ASGS, G3S or a combination thereof. In some embodiments, the linker is GGGGSGGGS (SEQ ID NO: 72).
[0057] In some embodiments, the serum albumin binding molecules provided herein comprise or are set forth in SEQ ID NO: 15 or 16, or an amino acid sequence having at least 80%, at least 90% sequence identity thereto.
[0058] In some embodiments, the immunoglobulin single variable domain in the aforementioned serum albumin binding molecule specifically binds to serum albumin, which can be rodent serum albumin (e.g., mouse serum albumin (mSA)), or primate serum albumin (e.g., macaque serum albumin (cySA), human serum albumin (HSA)). In some specific embodiments, the serum albumin is HSA.
[0059] In some alternatives, the serum albumin binding molecules of the present disclosure may comprise any of the aforementioned complete immunoglobulin single variable domains; or may comprise a functional portion of any of the aforementioned immunoglobulin single variable domains or variants thereof, such as CDR3, CDR3-FR4, CDR2-FR3-CDR3, CDR2-FR3-CDR3-FR4, FR2-CDR2-FR3-CDR3-FR4, CDR1-FR2-CDR2-FR3-CDR3-FR4, FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0060] In some embodiments, the variant of the functional portion of the immunoglobulin single variable domain may be a polypeptide that retains the serum albumin binding function of CDR3, CDR3-FR4, CDR2-FR3-CDR3, CDR2-FR3-CDR3-FR4, FR2-CDR2-FR3-CDR3-FR4, CDR1-FR2-CDR2-FR3-CDR3-FR4, or FR1-CDR1-FR2-CDR2-FR3-CDR3 and has at least 80% or at least 90% sequence homology therewith. For example, it may be a polypeptide that retains the serum albumin binding function of CDR3 and has a certain sequence homology therewith, for example, a polypeptide that has at least 80% or at least 90% sequence homology with any of the above-mentioned CDR3s.
[0061] In some embodiments, in the serum albumin binding molecules provided by the present disclosure, the immunoglobulin single variable domain can be covalently or non-covalently linked to any other macromolecular or small molecule compound as a carrier for extending half-life.
[0062] In some embodiments, the serum albumin binding molecules of the present disclosure comprise one or more therapeutic or diagnostic agents, wherein the therapeutic or diagnostic agent is covalently or non-covalently linked to the immunoglobulin single variable domain.
[0063] In some embodiments, the therapeutic or diagnostic agent is selected from the group consisting of a therapeutic or diagnostic protein, a nucleic acid, and a small molecule compound.
[0064] In some embodiments, the serum albumin binding molecules provided herein or the immunoglobulin single variable domains therein are present in an amount of ≤1×10 -7 M, for example, ≤2×10 -8 M, ≤1×10 -8 M, ≤9×10 -9 M, ≤8×10 -9 M, ≤7×10 -9 M, ≤6×10 -9 M, ≤5×10 -9 M, ≤4×10 -9 M, ≤3×10 -9 M, ≤2×10 -9 M, or ≤1×10 -9 M, or ≤9×10 -10 M, ≤8×10 -10 M, ≤7×10 -10 M, ≤6×10 -10 M, ≤5×10 -10 M, ≤4×10 -10 M, ≤3×10 -10 M, ≤2×10 -10M, ≤1×10 -10 M's K D The value binds to serum albumin, such as human serum albumin.
[0065] In some embodiments, the affinity of the serum albumin binding molecules provided by the present disclosure for human serum albumin is K D The value is 10nM-100nM, for example 10nM-50nM. D The method for detecting the value is commonly used in the art, such as that provided in Example 4 of the present disclosure.
[0066] In some embodiments, the serum albumin binding molecules provided herein have at least one activity selected from the group consisting of:
[0067] (a) ≤1×10 -7 M, for example, ≤1×10 -8 M's K D Value combined with HSA;
[0068] (b) does not detectably block the binding of serum albumin, such as HSA, to FcRn, such as human FcRn, in vivo and / or in vitro;
[0069] (c) when comprising a therapeutic or diagnostic agent, extending the plasma half-life of the therapeutic or diagnostic agent.
[0070] In some embodiments, the serum albumin binding molecules provided herein retain the advantageous properties of single domain antibodies (e.g., VHHs) and have an extended lifespan in the individual's circulation. Thus, such molecules can circulate in the serum of a subject for several days, thereby reducing the frequency of treatment, the inconvenience to the subject, and the cost of treatment.
[0071] In some embodiments, the half-life of the serum albumin binding molecules of the present disclosure can be controlled by the number of single variable domains that specifically bind to serum proteins present in the molecule.
[0072] In some embodiments, the serum albumin binding molecules of the present disclosure promote the binding of serum albumin to FcRn in vivo and / or in vitro.
[0073] Fusion protein
[0074] The present disclosure provides a fusion protein comprising a serum albumin binding domain and relaxin or an analog thereof, wherein the serum albumin binding domain comprises at least one immunoglobulin single variable domain, wherein the immunoglobulin single variable domain is any one of the immunoglobulin single variable domains disclosed above.
[0075] In some embodiments, the immunoglobulin single variable domain comprises the CDR1, CDR2, and CDR3 of any one of the following 1) to 5):
[0076] 1) CDR1, CDR2, and CDR3 in the amino acid sequence of any one of SEQ ID NOs: 6 and 18-27;
[0077] 2) CDR1, CDR2, and CDR3 in the amino acid sequence of SEQ ID NO: 7;
[0078] 3) CDR1, CDR2, and CDR3 as shown in SEQ ID NOs: 8, 9, and 10;
[0079] 4) CDR1, CDR2, and CDR3 as shown in SEQ ID NOs: 11, 12, and 13;
[0080] 5) CDR1 is X1SCX2G (SEQ ID NO: 64), wherein X1 is T or N, and X2 is M or L;
[0081] CDR2 is X3IYX4VGGSTFYX5X6SVKG (SEQ ID NO: 58), wherein X3 is S or T, X4 is T or M, X5 is T or A, and X6 is N or D;
[0082] CDR3 is GSPARCX7X8RDPTTFX9Y (SEQ ID NO: 59), wherein X7 is R or L, X8 is L or R, and X9 is D or N;
[0083] Wherein, one or more of the above X1 to X9 may be conservative amino acid mutations of their optional amino acids.
[0084] The above CDRs are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering systems, for example, the CDRs are defined according to the Kabat numbering system.
[0085] In some embodiments, the aforementioned immunoglobulin single variable domain is modified by any of the following: camel origin, or humanization, affinity maturation, removal of T cell epitopes, reduction of antibody deamidation, reduction of antibody aggregation and / or reduction of antibody isomerization, or a combination thereof.
[0086] In some embodiments, the framework regions in the humanized immunoglobulin single variable domain are derived from the human heavy chain variable region germline genes IGHV3-23 or IGVH3-66.
[0087] In some embodiments, the humanized immunoglobulin single variable domain comprises an amino acid mutation at at least one of the following positions: positions 20, 23, 27, 29, 30, 37, 44, 45, 47, 49, 74, 78, 83, and 84 (positions based on the EU numbering system);
[0088] For example, comprising at least one amino acid mutation selected from the group consisting of 20V, 23V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 49A, 74A, 78V, 83Q, or 84P;
[0089] For example, comprising a combination of amino acid mutations selected from any of the following:
[0090] F27N, F29Y, S30L, V37F, G44E, L45R, W47G;
[0091] L20V, F27N, F29Y, S30L, V37F, G44E, L45R, W47G;
[0092] A23V, F27N, F29Y, S30L, V37F, G44E, L45R, W47G;
[0093] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, S74A;
[0094] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, L78V;
[0095] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, S49A;
[0096] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, R83Q, A84P;
[0097] F27N, F29Y, S30L, V37F, G44E, L45R, W47G, A84P;
[0098] S30L, V37F, G44E, L45R, W47G, A84P; or
[0099] S30L, V37F, G44E, L45R, W47G.
[0100] In some embodiments, the immunoglobulin single variable domain comprises or is set forth in any one of SEQ ID NOs: 6, 18-27, or an amino acid sequence having at least 80% or at least 90% sequence identity thereto.
[0101] In some embodiments, the immunoglobulin single variable domain comprises or is set forth in SEQ ID NO: 7, or an amino acid sequence having at least 80% or at least 90% sequence identity thereto.
[0102] In some embodiments, the immunoglobulin single variable domain is a VHH, such as a camelid or humanized VHH.
[0103] In some embodiments, the relaxin or analog thereof in the fusion protein comprises an A chain and a B chain.
[0104] In some embodiments, the A chain has the amino acid sequence shown in any one of SEQ ID NOs: 31, 50, 52, 54, and 56, or an amino acid sequence having at least 90% sequence identity with any one of SEQ ID NOs: 31, 50, 52, 54, and 56, or an amino acid sequence having one or more amino acid additions, deletions, insertions, or substitutions compared to any one of SEQ ID NOs: 31, 50, 52, 54, and 56. For example, the A chain can be SEQ ID NO: 31 or 50 with 1, 2, 3, or 4 amino acids deleted at the N-terminus, or with 1, 2, 3, or 4 amino acids added.
[0105] In some embodiments, the B chain has an amino acid sequence as shown in any one of SEQ ID NOs: 32, 51, 53, 55, and 57, or an amino acid sequence having at least 90% sequence identity with any one of SEQ ID NOs: 32, 51, 53, 55, and 57, or an amino acid sequence having one or more amino acid additions, deletions, insertions, or substitutions compared to any one of SEQ ID NOs: 32, 51, 53, 55, and 57. For example, the B chain can be SEQ ID NO: 51 with one amino acid deleted at the N-terminus.
[0106] In some embodiments, the A chain and B chain of relaxin or its analog are any combination described above.
[0107] In some embodiments, the relaxin or analog thereof comprises the A chain and B chain combination of any one of the following 1)-7):
[0108] 1) Chain A shown in SEQ ID NO: 31 and Chain B shown in SEQ ID NO: 32;
[0109] 2) Chain A shown in SEQ ID NO: 50 and Chain B shown in SEQ ID NO: 51;
[0110] 3) Chain A shown in SEQ ID NO: 52 and Chain B shown in SEQ ID NO: 53;
[0111] 4) Chain A shown in SEQ ID NO: 54 and Chain B shown in SEQ ID NO: 55;
[0112] 5) Chain A shown in SEQ ID NO: 31 and Chain B shown in SEQ ID NO: 53;
[0113] 6) Chain A shown in SEQ ID NO: 52 and Chain B shown in SEQ ID NO: 32;
[0114] 7) Chain A shown in SEQ ID NO: 56 and chain B shown in SEQ ID NO: 57.
[0115] >Human RLN2 A chain
[0116] QLYSALANKCCHVGCTKRSLARFC (SEQ ID NO: 31)
[0117] >Human RLN2 B chain (delB1)
[0118] SWMEEVIKLCGRELVRAQIAICGMSTWS (SEQ ID NO: 32)
[0119] >Human RLN1 A chain
[0120] PYVALFEKCCLIGCTKRSLAKYC(SEQ ID NO: 50)
[0121] >Human RLN1 B chain
[0122] VAAKWKDDVIKLCGRELLVRAQIAICGMSTWS(SEQ ID NO: 51)
[0123] >Human RLN2 A chain (delA1-4)
[0124] ALANKCCHVGCTKRSLARFC (SEQ ID NO: 52)
[0125] >Human RLN2 B chain
[0126] DSWMEEVIKLCGRELVRAQIAICGMSTWS (SEQ ID NO: 53)
[0127] >Human RLN3 A chain
[0128] DVLAGLSSSCCKWGCSKSEISSLC (SEQ ID NO: 54)
[0129] >Human RLN3 B chain
[0130] RAAPYGVRLCGREFIRAVIFTCGGSRW (SEQ ID NO: 55)
[0131] >Human RLN2 A chain (Z 10 LYS)
[0132] X 10 LYSALANKCCHVGCTKRSLARFC, where X 10 Q or D
[0133] (SEQ ID NO: 56)
[0134] >Human RLN2 B chain (E mutated to D)
[0135] DSWMEEVIKLCGRDLVRAQIAICGMSTWS (SEQ ID NO: 57).
[0136] In some embodiments, the fusion protein comprises one aforementioned immunoglobulin single variable domain and one aforementioned relaxin or an analog thereof. In some embodiments, the fusion protein comprises one aforementioned immunoglobulin single variable domain and two aforementioned relaxins or an analog thereof. In some embodiments, the fusion protein comprises two aforementioned immunoglobulin single variable domains and one aforementioned relaxin or an analog thereof. In some embodiments, the fusion protein comprises two aforementioned immunoglobulin single variable domains and two aforementioned relaxins or an analog thereof.
[0137] In some embodiments, the fusion protein comprises a polypeptide as shown in any one of Formulas (I) to (IV) or any combination thereof: B-L1-A-L2-VHH Formula (I) A-L1-B-L2-VHH Formula (II) VHH-L2-B-L1-A Formula (III) VHH-L1-A-L1-B Formula (III)
[0138] Wherein, A is any of the aforementioned relaxin A chains, B is any of the aforementioned relaxin B chains, and L1 and L2 are linkers, which may be present or absent independently.
[0139] In some embodiments, L1 comprises an amino acid sequence selected from (GGGGQ)n (SEQ ID NO: 73), (GGGQ)n, (GGGGS)n, (PGPQ)n and (PGPA)n, wherein n is selected from an integer of 1-10, such as 3, 4, 5, 6, 7, 8.
[0140] In some embodiments, L1 comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 33-35, or an amino acid sequence having at least 90% sequence identity thereto.
[0141] In some embodiments, L2 comprises (G X S Y ) Z An amino acid sequence, wherein X, Y, and Z are independently selected from integers 1-10, for example, L2 is (GGGGS)z, and Z is selected from integers 1-10, for example, 3, 4, 5, 6, 7, or 8.
[0142] In some embodiments, L2 comprises an amino acid sequence as set forth in SEQ ID NO: 49, or an amino acid sequence having at least 90% sequence identity thereto.
[0143] In some embodiments, L2 comprises an amino acid sequence selected from any one of KR, KRKPTGYGSRKKR (SEQ ID NO: 65), KRKPTGYGSRKR (SEQ ID NO: 66), KRGGGPRR (SEQ ID NO: 60), KRGGGPKR (SEQ ID NO: 61), KRKPTGYGSKR (SEQ ID NO: 62), KRSLKR (SEQ ID NO: 63), or an amino acid sequence having at least 90% sequence identity thereto.
[0144] In some embodiments, the fusion protein is a single-chain protein.
[0145] In some embodiments, the fusion protein is a multimer, such as a dimeric protein.
[0146] Exemplary embodiments are given below:
[0147] A fusion protein comprising a serum albumin binding domain comprising an immunoglobulin single variable domain comprising CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 8, 9, and 10, or CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 11, 12, and 13; and relaxin or its analogue comprising the A and B chains as set forth in SEQ ID NOs: 31 and 32, or the A and B chains as set forth in SEQ ID NOs: 50 and 51, or the A and B chains as set forth in SEQ ID NOs: 52 and 53, or the A and B chains as set forth in SEQ ID NOs: 54 and 55, or the A and B chains as set forth in SEQ ID NOs: 31 and 53, or the A and B chains as set forth in SEQ ID NOs: 52 and 32, or the A and B chains as set forth in SEQ ID NOs: 56 and 57.
[0148] A fusion protein comprising a serum albumin binding domain and relaxin or an analog thereof, wherein the serum albumin binding domain comprises an immunoglobulin single variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 6, 18-27, or an amino acid sequence having at least 90% sequence identity thereto, or as set forth in SEQ ID NO: 7, or an amino acid sequence having at least 90% sequence identity thereto; and the relaxin or an analog thereof comprises the A and B chains as set forth in SEQ ID NOs: 31 and 32, or the A and B chains as set forth in SEQ ID NOs: 50 and 51, or the A and B chains as set forth in SEQ ID NOs: 52 and 53, or the A and B chains as set forth in SEQ ID NOs: 54 and 55, or the A and B chains as set forth in SEQ ID NOs: 31 and 53, or the A and B chains as set forth in SEQ ID NOs: 52 and 32, or the A and B chains as set forth in SEQ ID NOs: 56 and 57.
[0149] In some embodiments, a fusion protein is provided comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 36-43 or having at least 90% sequence identity thereto.
[0150] In some embodiments, the binding affinity of the fusion proteins of the present disclosure to the RXFP1 receptor is comparable to the binding affinity of native human relaxin 2 (SEQ ID NOs: 31 and 53). In other embodiments, the binding affinity of the fusion proteins of the present disclosure to the RXFP1 receptor is less than the binding affinity to native human relaxin 2 (SEQ ID NOs: 31 and 53). In other embodiments, the binding affinity of the fusion proteins of the present disclosure to the RXFP1 receptor is greater than the binding affinity to native human relaxin 2 (SEQ ID NOs: 31 and 53).
[0151] In some embodiments, the fusion proteins of the present disclosure have significantly increased half-life (t ) compared to native human relaxin 2 (SEQ ID NOs: 31 and 53), for example, having an in vivo half-life (t 1 / 2 ), ranging from a dozen hours to more than ten days in different species.
[0152] In some embodiments, the fusion protein of the present disclosure is ≤1×10 -7 M, for example, ≤1×10 -8 M's K D Value combined with HSA.
[0153] In some embodiments, the fusion proteins of the present disclosure do not block the binding of serum albumin to FcRn in vivo and / or in vitro.
[0154] The fusion proteins disclosed herein encompass pharmaceutically acceptable salts thereof.
[0155] Polynucleotides and vectors
[0156] In some embodiments, polynucleotides are provided that encode the serum albumin binding molecules of the present disclosure.
[0157] In some embodiments, polynucleotides are provided that encode the fusion proteins of the present disclosure.
[0158] The polynucleotide may be RNA, DNA or cDNA.According to some embodiments of the present disclosure, the polynucleotide of the present disclosure is an isolated polynucleotide.
[0159] The polynucleotides of the present disclosure may also be in the form of a vector, may be present in a vector and / or may be part of a vector, such as a plasmid, cosmid, YAC or viral vector. The vector may in particular be an expression vector, i.e. a vector that provides for expression of the serum albumin binding molecule in vitro and / or in vivo (i.e. in a suitable host cell, host organism and / or expression system). The expression vector typically comprises at least one polynucleotide of the present disclosure, which is operably linked to one or more suitable expression control elements (e.g., promoters, enhancers, terminators, etc.). It is common knowledge for those skilled in the art to select such elements and their sequences for expression in a particular host. Regulatory elements and other elements that are useful or necessary for expression of the serum albumin binding molecules of the present disclosure are, for example, promoters, enhancers, terminators, integration factors, selection markers, leader sequences, reporter genes.
[0160] The polynucleotides of the present disclosure can be prepared or obtained by known means (eg, by automated DNA synthesis and / or recombinant DNA technology) based on the information of the amino acid sequence of the polypeptides of the present disclosure, and / or can be isolated from suitable natural sources.
[0161] host cells
[0162] In some embodiments, host cells are provided that express or are capable of expressing one or more serum albumin binding molecules of the present disclosure, and / or recombinant host cells containing a polynucleotide or vector of the present disclosure.
[0163] In some embodiments, the host cell is a bacterial cell, a fungal cell, or a mammalian cell.
[0164] Examples of bacterial cells include cells of gram-negative bacterial strains (e.g., Escherichia coli strains, Proteus strains, and Pseudomonas strains) and gram-positive bacterial strains (e.g., Bacillus strains, Streptomyces strains, Staphylococcus strains, and Lactococcus strains).
[0165] Exemplary fungal cells include cells of species of the genera Trichoderma, Neurospora, and Aspergillus; or cells of species of the genera Saccharomyces (e.g., Saccharomyces cerevisiae), Schizosaccharomyces (e.g., Schizosaccharomyces pombe), Pichia (e.g., Pichia pastoris and Pichia methanolica), and Hansenula.
[0166] Illustratively, mammalian cells include, for example, HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, and the like.
[0167] The present disclosure may also be used with amphibian cells, insect cells, plant cells, and any other cells known in the art for expressing heterologous proteins.
[0168] The cells of the present disclosure are incapable of developing into complete plants or animals.
[0169] Production or preparation method
[0170] The present disclosure provides a method for preparing the serum albumin binding molecule or fusion protein of the present disclosure, comprising:
[0171] - culturing the host cell of the present disclosure under conditions that allow expression of the serum albumin binding molecule or fusion protein of the present disclosure; and
[0172] - recovering the serum albumin binding molecule or fusion protein expressed by the host cell from the culture; and
[0173] - Optionally, further purification and / or modification of the serum albumin binding molecules or fusion proteins of the present disclosure is involved.
[0174] The serum albumin binding molecules or fusion proteins of the present disclosure can be produced intracellularly in the cells as described above (e.g., in the cytoplasm, in the periplasm, or in inclusion bodies), then isolated from the host cells and optionally further purified; or they can be produced extracellularly (e.g., in the culture medium in which the host cells are cultured), then isolated from the culture medium and optionally further purified.
[0175] Methods and reagents for recombinantly producing polypeptides or proteins, such as specific expression vectors, transformation or transfection methods, selection markers, methods for inducing protein expression, and culture conditions, are known in the art. Similarly, isolation and purification techniques suitable for producing target proteins, such as binding molecules or antibodies, are well known to those skilled in the art. Methods for producing and purifying antibodies are well known in the art and can be found in the Cold Spring Harbor Laboratory Manual (Chapters 5-8 and 15). The engineered antibodies disclosed herein can also be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into expression vectors. Recombinant immunoglobulin expression vectors can be stably transfected into cells. Mammalian expression systems result in glycosylation of antibodies, particularly at the highly conserved N-terminus of the Fc region. Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are expanded in serum-free medium in bioreactors to produce antibodies. The culture fluid containing the secreted antibodies can be purified and collected using conventional techniques. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieves and ion exchange. The resulting product should be immediately frozen, such as at -70°C, or lyophilized.
[0176] However, the serum albumin binding molecules or fusion proteins of the present disclosure can also be obtained by other methods of producing proteins known in the art, such as chemical synthesis, including solid phase or liquid phase synthesis.
[0177] Composition
[0178] In some embodiments, the composition is a pharmaceutical composition, which contains a preventively or therapeutically effective amount of the serum albumin binding molecule or fusion protein of the present disclosure as described above, and / or a polynucleotide encoding the serum albumin binding molecule or fusion protein, and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients.
[0179] In some embodiments, the pharmaceutical composition may contain 0.01 to 99% by weight of the serum albumin binding molecule or fusion protein per unit dose. In other embodiments, the pharmaceutical composition may contain 0.1 to 2000 mg of the serum albumin binding molecule or fusion protein per unit dose; in some embodiments, 1 to 1000 mg.
[0180] Kits and Tests
[0181] The present disclosure provides a kit or product comprising any of the aforementioned serum albumin binding molecules of the present disclosure and / or a nucleic acid molecule encoding a serum albumin binding molecule of the present disclosure.
[0182] The present disclosure provides a composition for detecting serum albumin, comprising the serum albumin binding molecules of the present disclosure. The present disclosure also provides a method, system or device for detecting serum albumin in vivo or in vitro, comprising using the serum albumin binding molecules of the present disclosure.
[0183] In some embodiments, an in vitro detection method, system, or apparatus may, for example, comprise (1) contacting a sample with a serum albumin binding molecule of the present disclosure; (2) detecting complexes formed between the serum albumin binding molecule of the present disclosure and the sample; and / or (3) contacting a reference sample (e.g., a control sample) with an antibody; and (4) determining the extent of complex formation between the antibody and the sample by comparison with the reference sample. A change (e.g., a statistically significant change) in complex formation in the sample or subject, as compared to the control sample or subject, indicates the presence of serum albumin in the sample.
[0184] In other embodiments, the in vivo detection method, system or device may comprise: (1) administering a serum albumin binding molecule of the present disclosure to a subject; and (2) detecting the formation of a complex between the serum albumin binding molecule of the present disclosure and the subject. Detection may comprise determining the location or time of complex formation. Antibodies that bind to the serum albumin binding molecule may be directly or indirectly labeled with a detectable substance to facilitate detection of bound or unbound antibodies. Suitable detectable substances include a variety of enzymes, prosthetic groups, fluorescent substances, luminescent substances and radioactive substances. Complex formation between the serum albumin binding molecule of the present disclosure and serum albumin may be detected by measuring or visualizing antibodies that are bound or unbound to the serum albumin binding molecule. Conventional detection assays may be used, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) or tissue immunohistochemistry. In some embodiments, the presence of serum albumin in a sample is analyzed by a competitive immunoassay using a standard labeled with a detectable substance and an unlabeled serum albumin binding molecule of the present disclosure. The living sample to be detected or measured can be tissue cells, blood, plasma, serum, pancreatic juice, urine, feces, tissue fluid or culture medium.
[0185] In some embodiments, the serum albumin binding molecules of the present disclosure may be labeled with a fluorophore or chromophore for detection purposes.
[0186] Methods for treating and preventing diseases and pharmaceutical uses
[0187] The present disclosure provides a method for extending the plasma half-life of a therapeutic or diagnostic agent, comprising covalently or non-covalently linking a serum albumin binding molecule or an immunoglobulin single variable domain thereof to the therapeutic or diagnostic agent. The linking method is known in the art or can be any future method, for example, the molecule can be fused by chemical coupling, fused at the DNA level, fused at the mRNA level, or fused at the protein level.
[0188] In some embodiments, the therapeutic or diagnostic molecule can be a therapeutic target or a diagnostic target. The target can be any protein, peptide, nucleic acid, oligonucleic acid, sugar, polysaccharide, or glycoprotein of therapeutic or diagnostic use. Examples include, but are not limited to, receptors, receptor ligands, viral coat proteins, immune system proteins, hormones, enzymes, antigens, cell signaling proteins, or fragments thereof.
[0189] In some embodiments, the plasma half-life of the therapeutic or diagnostic agent linked to the serum albumin binding molecules of the present disclosure or immunoglobulin single variable domain thereof is increased by at least 1.5 times, preferably at least 2 times, such as at least 5 times, such as at least 10 times or greater than 20 times compared to before linkage; for example, the increased plasma half-life can be greater than 1 hour, preferably greater than 2 hours, more preferably greater than 6 hours, such as greater than 12 hours, or even greater than 24, 48 or 72 hours compared to before linkage.
[0190] The present disclosure provides a method for treating and / or preventing a disease, comprising administering a therapeutically and / or prophylactically effective amount of the serum albumin binding molecule or fusion protein of the present disclosure to a subject in need thereof.
[0191] The present disclosure also provides a method for treating and / or preventing a disease using a serum albumin binding molecule or fusion protein, which comprises administering a therapeutically and / or preventively effective amount of the serum albumin binding molecule or fusion protein of the present disclosure to a subject in need thereof.
[0192] The present disclosure also provides use of the serum albumin binding molecule in preparing a medicament for treating and / or preventing a disease.
[0193] In some embodiments, the disease is a fibrotic disease or a cardiovascular disease.
[0194] In some specific embodiments, the cardiovascular disease is heart failure (HF) or myocardial hypertrophy. BRIEF DESCRIPTION OF THE DRAWINGS
[0195] Figure 1A to Figure 1C show the results of ELISA binding experiments of serum albumin binding molecules.
[0196] FIG1A shows the results of an ELISA binding assay of anti-HSA antibodies and human serum albumin (HSA).
[0197] FIG1B shows the results of an ELISA binding experiment of anti-HSA antibodies binding to monkey serum albumin (CySA).
[0198] FIG1C shows the results of an ELISA binding experiment of anti-HSA antibodies binding to mouse serum albumin (mSA).
[0199] FIG2A and FIG2B show the experimental results of the effect of anti-HSA antibodies on the binding between FcRn and HSA.
[0200] FIG3 is a concentration-time curve of the anti-HSA antibody in plasma after intravenous administration in a pharmacokinetic study of mice.
[0201] 4A and 4B show the results of pharmacokinetic studies of anti-HSA antibodies in mice.
[0202] Figure 4A shows the T values of anti-HSA antibodies in plasma calculated using a non-compartmental model. 1 / 2 Parameter comparison results.
[0203] FIG4B shows the comparison results of the Cl_obs (mL / (min*kg)) parameter.
[0204] FIG5 is a schematic diagram of the structure of the fusion protein (Formula (III)) disclosed herein.
[0205] FIG6A shows the results of in vitro activity detection of the fusion protein in THP1 cells in the absence of HSA.
[0206] FIG6B shows the results of in vitro activity testing of the fusion protein in THP1 cells in a system containing 1% HSA.
[0207] FIG7A is a plasma drug-dose curve of the fusion protein in a mouse model.
[0208] FIG7B is a plasma drug-dose curve of the fusion protein in a rat model.
[0209] FIG8 shows the heart weight / tibia length ratio of the ISO myocardial hypertrophy model in the experiment of the effect of fusion protein on myocardial hypertrophy in mice. DETAILED DESCRIPTION
[0210] definition
[0211] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in the present disclosure, all other technical and scientific terms used in the present disclosure have the meanings commonly understood by those skilled in the art to which the present disclosure belongs.
[0212] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).
[0213] “Antibody” or “immunoglobulin”, whether referring to a heavy chain antibody or a conventional tetrapeptide chain antibody composed of two heavy chains and two light chains connected by interchain disulfide bonds, is used as a general term to include full-length antibodies, individual chains thereof, and all parts, domains or fragments thereof (including but not limited to antigen-binding domains or fragments, such as VHH domains or VH / VL domains).
[0214] "Sequence" (for example, in terms such as "immunoglobulin sequence", "antibody sequence", "single variable domain sequence", "VHH sequence" or "protein sequence") should generally be understood to include both the relevant amino acid sequence and the nucleic acid sequence or nucleotide sequence encoding the sequence, unless the present disclosure requires further limited interpretation.
[0215] A "domain" of a polypeptide or protein refers to a folded protein structure that is capable of maintaining its tertiary structure independently of the rest of the protein. In general, a domain is responsible for a single functional property of a protein and in many cases can be added, removed, or transferred to other proteins without loss of function of the rest of the protein and / or the domain.
[0216] "Immunoglobulin domain" refers to the globular region of an antibody chain.
[0217] An "immunoglobulin variable domain" refers to a domain essentially consisting of "Framework Region 1" (FR1), "Framework Region 2" (FR2), "Framework Region 3" (FR3), and "Framework Region 4" (FR4), as well as "Complementarity Determining Region 1" (CDR1), "Complementarity Determining Region 2" (CDR2), and "Complementarity Determining Region 3" (CDR3). Therefore, the general structure (or sequence) of a variable domain can be represented as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The variable domain confers specificity for an antigen by having an antigen-binding site.
[0218] "Antibody framework (FR)" refers to the portion of a variable domain that serves as a scaffold for the antigen binding loops (CDRs) of that variable domain.
[0219] "Immunoglobulin single variable domain" is generally used to refer to an immunoglobulin variable domain (which may be a heavy or light chain domain, including a VH, VHH or VL domain) that can form a functional antigen binding site without interacting with other variable domains (e.g., without the VH / VL interactions required between the VH and VL domains of conventional four-chain monoclonal antibodies). Examples of "immunoglobulin single variable domains" include nanobodies (including VHH, humanized VHH and / or camelized VH, e.g., camelized human VH), IgNAR, domains, (single domain) antibodies that are VH domains or derived from VH domains (such as dAbs), and antibodies that are VH domains or derived from VH domains. TM ) and (single domain) antibodies (such as dAbs) as the VL domain or derived from the VL domain TM ). Immunoglobulin single variable domains based on and / or derived from heavy chain variable domains (such as VH or VHH domains) are generally preferred. A specific example of an immunoglobulin single variable domain is a "VHH domain" (or simply "VHH") as defined below.
[0220] "VHH domain", also known as heavy chain single domain antibody, VHH, V HH Domain, VHH antibody fragment, VHH antibody, nanobody, is the variable domain of the antigen-binding immunoglobulin called "heavy chain antibody" (i.e., "antibody lacking light chain") (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)). The term "VHH domain" is used to distinguish the variable domain from the VH and VL present in conventional tetrapeptide chain structure antibodies. The VHH domain specifically binds to the epitope without the need for other antigen-binding domains (for the VH or VL domain in conventional tetrapeptide chain structure antibodies, the epitope is recognized by the VL domain together with the VH domain). The VHH domain is a small, stable and efficient antigen recognition unit formed by a single immunoglobulin domain. The terms "heavy chain single domain antibody", "VHH domain", "VHH", "V HH domain", "VHH antibody fragment", "VHH antibody", as well as" "VHH domain" ("Nanobody" is a trademark of Ablynx NV, Ghent, Belgium) can be used interchangeably. "VHH domain" includes but is not limited to natural antibodies produced by camelids, antibodies produced by camelids that have been humanized, or antibodies obtained by phage display technology. The total number of amino acid residues in a VHH domain will usually be in the range of 110 to 120, often between 112 and 115. However, it should be noted that smaller and longer sequences may also be suitable for the purposes described in the present disclosure. Methods for obtaining VHHs that bind to specific antigens or epitopes have been previously disclosed in the following literature: R. van der Linden et al., Journal of Immunological Methods, 240 (2000) 185-195; Li et al., J Biol Chem., 287 (2012) 13713-13721; Deffar et al., African Journal of Biotechnology Vol.8(12), pp.2645-2652, 17 June, 2009 and WO94 / 04678.
[0221] As is well known in the art for VH and VHH domains, the total number of amino acid residues in each CDR may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering (i.e., one or more positions numbered according to Kabat may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than allowed by Kabat numbering). This means that, in general, the numbering according to Kabat may or may not correspond to the actual numbering of amino acid residues in the actual sequence. Other numbering systems or coding conventions include Chothia, IMGT, and AbM.
[0222] "Humanized antibodies", also known as CDR-grafted antibodies, refer to antibodies produced by transplanting non-human CDR sequences into the variable region framework of a human antibody. This can overcome the strong immune response induced by chimeric antibodies due to the large amount of non-human protein components they carry. In order to avoid a decrease in activity while also reducing immunogenicity, the fully human antibody variable region can be subjected to minimal reverse mutations to maintain activity. Examples of "humanization" include the humanization of a VHH domain derived from Camelidae by replacing one or more amino acid residues in the amino acid sequence of the original VHH sequence with one or more amino acid residues present at corresponding positions in the VH domain of a human conventional tetrapeptide chain structure antibody. The humanized VHH domain may contain one or more fully human framework region sequences, and in some specific embodiments, may contain the human framework region sequence of IGHV3. Humanization methods such as protein surface amino acid humanization (resurfacing) and antibody humanization universal framework transplantation (CDR grafting to a universal framework), i.e., CDR "grafting" onto other "scaffolds" (including but not limited to human scaffolds or non-immunoglobulin scaffolds). Scaffolds and techniques suitable for the CDR transplantation are known in the art. For example, the germline DNA sequences of human heavy and light chain variable region genes can be found in the VBase human germline sequence database, as well as in Kabat, EA et al., 1991 Sequences of Proteins of Immunological Interest, 5th edition. The humanized antibodies disclosed herein also include humanized antibodies that are further subjected to affinity maturation of CDRs by phage display. In addition, in order to avoid a decrease in immunogenicity and the resulting decrease in activity, the human antibody variable region framework sequences can be subjected to minimal reverse mutation or back mutation to maintain activity.
[0223] One skilled in the art can determine the amino acid sequence boundaries of an antibody CDR using any of a number of known numbering schemes, including those described in Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefran et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme); each of which is incorporated by reference in its entirety.
[0224] "Epitope" or the interchangeable term "antigenic determinant" refers to any antigenic determinant on the antigen to which an antibody is bound. Antigenic determinants typically comprise chemically active surface groups of molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural characteristics and / or specific charge characteristics. For example, an epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 continuous or discontinuous amino acids in a unique spatial conformation, which can be a "linear" epitope or a "conformational" epitope. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996). In a linear epitope, all interacting points between an antigen and an interacting molecule (such as an antibody) exist linearly along the primary amino acid sequence of the antigen. In a conformational epitope, the interacting points exist across amino acid residues separated from each other. Many epitope mapping techniques well known in the art can be used to identify the epitope of a given antigen. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996). For example, linear epitopes can be determined by, for example, simultaneously synthesizing a large number of peptides on a solid support, where the peptides correspond to portions of the protein molecule, and reacting the peptides with antibodies while still attached to the support. These techniques are known in the art and are described, for example, in U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA 81: 3998-4002; Geysen et al. (1986) Molec. Immunol. 23: 709-715. Conformational epitopes can also be identified by determining the spatial configuration of amino acids, such as by, for example, x-ray crystallography and two-dimensional nuclear magnetic resonance. Antibodies can be screened for competitive binding to the same epitope using conventional techniques known to those skilled in the art. For example, competition and cross-competition studies can be performed to obtain antibodies that compete or cross-compete with each other for antigen binding. A high-throughput method for obtaining antibodies that bind to the same epitope based on their cross-competition is described in International Patent Application WO 03 / 48731. Thus, antibodies and antigen-binding fragments thereof that compete with the antibody molecules of the present disclosure for binding to the same epitope on serum albumin can be obtained using conventional techniques known to those skilled in the art.
[0225] In general, the term "specificity" refers to the number of different types of antigens or epitopes to which a particular antigen binding molecule or antigen binding protein (e.g., a serum albumin binding molecule of the present disclosure) can bind. The specificity of an antigen binding protein can be determined based on its affinity and / or avidity. The dissociation equilibrium constant (K) of the antigen and the antigen binding protein is determined by the affinity and / or avidity of the antigen binding protein. D ) is a measure of the binding strength between an epitope and the antigen binding site on an antigen binding protein: K D The smaller the value, the stronger the binding strength between the epitope and the antigen binding protein (or, affinity can also be expressed as a binding constant (K a ), which is 1 / K D As will be appreciated by those skilled in the art, affinity can be determined in a known manner, depending on the specific antigen of interest. Avidity is a measure of the strength of binding between an antigen binding protein (e.g., an immunoglobulin, an antibody, an immunoglobulin single variable domain, or a polypeptide containing the same) and the relevant antigen. Avidity is related to both the affinity of the antigen binding site on the antigen binding protein and the number of relevant binding sites present on the antigen binding protein.
[0226] "Serum albumin binding domain" means any polypeptide that can specifically bind to serum albumin or its epitope. "Serum albumin binding molecule" means any molecule that can specifically bind to serum albumin or its epitope, including but not limited to proteins and polypeptides. Serum albumin binding molecules may include antibodies or antigen-binding fragments thereof as defined in the present disclosure that are directed against serum albumin or its epitope, or conjugates or fusion proteins comprising the antibodies or antigen-binding fragments thereof. Antigen-binding fragments are, for example, sdAbs or bispecific antibodies or multispecific antibodies. The serum albumin binding molecules of the present disclosure may comprise at least one (e.g., 2, 3, 4 or more) immunoglobulin single variable domains (e.g., VHH) that bind to serum albumin. In addition to the immunoglobulin single variable domains, the serum albumin binding molecules of the present disclosure may also comprise a linker and / or a portion having the function of an effector molecule, the effector molecule including but not limited to a diagnostic agent or therapeutic agent, for example, an anti-tumor agent, an immunomodulator, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.
[0227] An "affinity matured" serum albumin antibody (eg, VHH) has one or more changes in one or more CDRs which result in an increase in affinity for serum albumin compared to its parent anti-serum albumin antibody. Affinity matured anti-serum albumin antibodies can be prepared by methods known in the art, for example, as described in Marks et al., 1992, Biotechnology 10:779-783 or Barbas et al., 1994, Proc. Nat. Acad. Sci, USA 91:3809-3813; Shier et al., 1995, Gene 169:147-155; Yelton et al., 1995, Immunol. 155:1994-2004; Jackson et al., 1995, J. Immunol. 154(7):3310-9; and Hawkins et al., 1992, J. MoI. Biol. 226(3):889-896; KS Johnson and RE Hawkins, "Affinity maturation of antibodies using phage display", Oxford University Press 1996.
[0228] "Back mutation" refers to the mutation of the amino acid residues in the FR region of a human antibody to the amino acid residues at the corresponding position of the original source antibody. This is usually done to avoid the decrease in immunogenicity and activity caused by the humanized antibody. The humanized antibody variable region can be subjected to minimal reverse mutation to maintain the activity of the antibody.
[0229] Typically, the serum albumin binding molecules of the present disclosure will be expressed as preferably 10 -7 to 10 -10 Mole / liter (M), more preferably 10 -8 to 10 -10 mol / L, even more preferably 10 -9 to 10 -10 or lower dissociation constant (K D ), and / or with at least 10 -7 M, preferably at least 10 -8 M, more preferably at least 10 -9 M, more preferably at least 10 -10 The binding constant (K a ) binds to the antigen to be bound (ie serum albumin). Any -4 M's K DValues are generally considered to indicate nonspecific binding. Specific binding of an antigen-binding protein to an antigen or epitope can be determined by any suitable means known in the art, including, for example, surface plasmon resonance (SPR) assays, Scatchard assays, and / or competitive binding assays (e.g., radioimmunoassays (RIA), enzyme immunoassays (ELISA), and sandwich competitive assays as described herein.
[0230] The terms "inhibit" or "block" are used interchangeably and encompass both partial and complete inhibition / blocking.
[0231] As used herein, "homology" and "identity" refer to sequence similarity between two polynucleotide sequences or between two polypeptides. When a position in the two compared sequences is occupied by the same base or amino acid monomer subunit, for example, if every position in two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences match or are homologous, then the two sequences are 60% homologous; if 95 out of 100 positions in the two sequences match or are homologous, then the two sequences are 95% homologous. Generally speaking, a comparison is made when the two sequences are aligned to obtain the maximum percent homology.
[0232] "Conservative amino acid mutation" or "conservative (amino acid) substitution" refers to the substitution of one or more amino acid residues in a protein or polypeptide with a conservative amino acid, wherein the chemical structures of the amino acid residues before and after the substitution are similar, and the substitution has little or no effect on the function, activity, or other biological properties of the protein or polypeptide. Such conservative amino acid substitutions are well known in the art. For example, a conservative amino acid substitution preferably involves the substitution of one amino acid residue within the following groups (i)-(v) with another amino acid residue within the same group:
[0233] (i) Small aliphatic nonpolar or weakly polar residues: Ala, Ser, Thr, Pro and Gly;
[0234] (ii) polar negatively charged residues and their (uncharged) amides: Asp, Asn, Glu, and Gln;
[0235] (iii) polar positively charged residues: His, Arg, and Lys; (iv) larger aliphatic nonpolar residues: Met, Leu, Ile, Val, and Cys; and
[0236] (v) Aromatic residues: Phe, Tyr and Trp.
[0237] Particularly preferred conservative amino acid substitutions are as follows: Ala is substituted by Gly or Ser; Arg is substituted by Lys; Asn is substituted by Gln or His; Asp is substituted by Glu; Cys is substituted by Ser; Gln is substituted by Asn; Glu is substituted by Asp; Gly is substituted by Ala or Pro; His is substituted by Asn or Gln; Ile is substituted by Leu or Val; Leu is substituted by Ile or Val; Lys is substituted by Arg, Gln or Glu; Met is substituted by Leu, Tyr or Ile; Phe is substituted by Met, Leu or Tyr; Ser is substituted by Thr; Thr is substituted by Ser; Trp is substituted by Tyr; Tyr is substituted by Trp or Phe; Val is substituted by Ile or Leu.
[0238] "Nucleic acid," "nucleic acid molecule," or "polynucleotide" are used interchangeably in this disclosure to refer to any DNA or RNA molecule, whether single-stranded or double-stranded, and, in the case of single-stranded sequences, its complementary sequence, preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0239] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. In one embodiment, a vector is a "plasmid", which refers to a circular double-stranded DNA loop into which another DNA segment can be connected. In another embodiment, a vector is a viral vector, in which another DNA segment can be connected to a viral genome. The vector in the present disclosure can autonomously replicate in the host cell having been introduced therein (e.g., a bacterial vector and an additional mammalian vector having a bacterial origin of replication) or can be integrated into the genome of the host cell after introducing the host cell, thereby replicating (e.g., a non-additional mammalian vector) with the host genome.
[0240] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such designations include progeny. Thus, "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of passages. It will also be understood that all progeny may not be precisely identical in DNA content, due to deliberate or unintentional mutations. Mutant progeny that possess the same function or biological activity as that screened for in the originally transformed cell are included. Where a different designation is intended, this is clear from the context.
[0241] "Host cell" includes individual cells or cell cultures that can be or have been recipients of vectors for incorporating nucleic acid inserts. Host cells include the progeny of a single host cell, and due to natural, accidental, or intentional mutations, the progeny may not necessarily be identical (in morphology or genomic DNA complement) to the original parent cell. Host cells include cells transfected and / or transformed in vivo with the nucleic acids of the present disclosure. "Cell," "cell line," and "cell culture" are used interchangeably, and all such designations include their progeny. It should also be understood that, due to intentional or unintentional mutations, all progeny may not be precisely identical in terms of DNA content. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included.
[0242] A "pharmaceutical composition" refers to a mixture containing one or more fusion proteins, serum albumin binding molecules, polynucleotides described herein, and other components, such as physiologically / pharmaceutically acceptable carriers, diluents, buffers, or excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, promote absorption of the active ingredient, and thereby exert its biological activity.
[0243] "Administer," "apply," and "treat" as applied to an animal, human, subject, cell, tissue, organ, or biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, human, subject, cell, tissue, organ, or biological fluid. "Administer," "apply," and "treat" can refer to, for example, therapeutic, pharmacokinetics, diagnostics, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administer," "apply," and "treat" also mean the in vitro and ex vivo treatment of a cell by an agent, a diagnostic, a binding composition, or by another cell. "Treatment," as applied to humans, veterinary medicine, or research subjects, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.
[0244] "Treatment" means administering an internal or external therapeutic agent (such as a fusion protein of the present disclosure) to a subject having one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, a therapeutic agent is administered to a treated patient or population in an amount effective to alleviate one or more symptoms of a disease to induce regression of such symptoms or to inhibit the development of such symptoms to any clinically measurable degree. The amount of a therapeutic agent that is effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") can vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether the symptoms of the disease have been alleviated can be evaluated by any clinical test method commonly used by a physician or other health care professional to evaluate the severity or progression of the symptoms. Although embodiments of the present disclosure (e.g., methods of treatment or articles of manufacture) may not be effective in alleviating every symptom of the target disease, they should alleviate the target disease symptoms in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.
[0245] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. "And / or" should be taken as specifically disclosing that each of the two specified features or components has or does not have the other. Thus, the term "and / or" as used in phrases such as "A and / or B" in this disclosure includes "A and B," "A or B," "A" (alone), and "B" (alone). Unless the context clearly requires otherwise, throughout the specification and claims, the words "comprising," "having," "including," etc. should be understood to have an inclusive sense, rather than an exclusive or exhaustive sense; that is, the sense of "including but not limited to."
[0246] The "subject" and "patient" of the present disclosure refer to mammals, especially primates, and especially humans.
[0247] The ordinal numbers "first", "second", "L1", "L2", etc. in the present disclosure are not intended to limit the quantity, level, grade, or sequence, and their purpose is only to distinguish different elements, steps, and technical features.
[0248] Example
[0249] The present disclosure is further described below with reference to the following examples, but these examples are not intended to limit the scope of this disclosure. Experimental methods in the examples herein where specific conditions are not specified generally follow conventional conditions, such as those in the Cold Spring Harbor Laboratory Manual of Antibody Techniques and the Molecular Cloning Manual, or the conditions recommended by the raw material or product manufacturer. Reagents where the specific source is not specified are commercially available.
[0250] Example 1. Preparation of serum albumin antigen and detection protein
[0251] 1. Design and expression of human serum albumin:
[0252] Using human serum albumin (HSA) as a template, the amino acid sequence of a detection protein with some C-terminal amino acids missing was designed.
[0253] Full-length amino acid sequence of human serum albumin:
[0254] (Note: The italic underlined part is the signal peptide; the italic bold part is the propeptide).
[0255] The albumin-FcRn binding region is located in the third domain of the albumin molecule. Based on the molecular simulation structure, an albumin molecule was designed that lacked some amino acids in the third domain of the C-terminus (and an Avi-his tag was fused to the C-terminus):
[0256] (Note: The italics are Avi-his tags).
[0257] 2. Full-length amino acid sequence of monkey serum albumin:
[0258] (Note: The italic underlined part is the signal peptide; the italic bold part is the propeptide).
[0259] 3. Full-length amino acid sequence of mouse serum albumin:
[0260] (Note: The italic underlined part is the signal peptide; the italic bold part is the propeptide).
[0261] 4. Rat (Rat) serum albumin full-length amino acid sequence:
[0262] (Note: The italic underlined part is the signal peptide; the italic bold part is the propeptide).
[0263] Example 2. Screening of antibodies specifically binding to human serum albumin (HSA)
[0264] 1. Camel Immunity
[0265] Commercially available serum albumin extracted from human blood (Sigma, Cat. No. 126658) was used to immunize native Bactrian camels from Inner Mongolia. Five milliliters of pre-immune camel serum was collected and separated. Freund's complete or incomplete adjuvant was mixed with the antigen at a volume ratio of 1:1, and multiple immunizations were performed subcutaneously (100 μg protein per camel per immunization). Booster immunizations were performed every two weeks, and titers were measured after four immunizations. Plates were coated with 5 μg / mL human serum albumin (HSA) (Costar, Cat. No. 9018) at 100 μL / well and incubated at 4°C overnight. The next day, the plates were washed three times with PBST (0.05% Tween 20), at 300 μL / well, followed by blocking with 4% skim milk powder and incubation at 37°C for 2 hours. After washing, serial dilutions of the immune camel serum were added and incubated at 37°C for 1 hour. Negative controls consisted of the same serial dilutions of pre-immune serum and blank PBS solution. After incubation, the cells were washed three times with PBST and then incubated at 37°C for 1 hour with a horseradish peroxidase-conjugated goat anti-camel Fc polyclonal antibody (Thermo, Cat. No. A16060, 1:5000 dilution). The cells were then washed again and developed with TMB colorimetric buffer. The color was terminated with 1M sulfuric acid and the absorbance was read at OD 450 nm using a SpectraMax M5 microplate reader. The titer was determined at a 1:51200 dilution. If the titer met the criteria, peripheral blood was collected from the camels for library preparation.
[0266] 2. Phage Library Construction
[0267] 100-200 mL of camel peripheral blood was collected and peripheral blood lymphocytes (PBMCs) were separated using the Ficoll method. The cell count was 1.2 × 10 8 Add Trizol reagent and resuspend (1×10 7 cells / mL Trizol) to lyse the cells and place on ice for 5 minutes; centrifuge at 13000 rpm for 3 minutes, remove the supernatant, and discard the precipitate; add 1 / 5 volume of chloroform, shake vigorously for 30-60 seconds, and let it stand in an ice bath for 2 minutes; centrifuge at 13000 rpm for 10 minutes, aspirate the upper aqueous phase into a new 1.5 mL tube; add an equal volume of isopropanol, mix well, and let it stand at -20°C for 30 minutes; centrifuge at 13000 rpm for 10 minutes, remove the supernatant, and retain the precipitate; wash the precipitate with pre-cooled 75% ethanol and let it stand at room temperature for 5-10 minutes; add 600 μL of RNase-removed deionized water, redissolve it, obtain RNA, reverse transcribe it to obtain cDNA, and construct a phage library.
[0268] 3. Screening of phage libraries
[0269] An HSA protein lacking some amino acids in the C-terminal third domain (also known as a truncated HSA, the sequence of which is shown in SEQ ID NO: 2) was expressed and purified in HEK293 cells, and this protein was used to screen a phage library to obtain antibodies with affinity for HSA.
[0270] 10 μg of the above-mentioned truncated HSA-avi-biotin protein was bound to 1 mg of Dynabeads M-280 streptavidin (Invitrogen, Cat No. 11206D) and allowed to stand at room temperature for one hour. The beads were then washed three times with 1× PBS and blocked with 2% skim milk at room temperature for two hours. The camel heavy chain single domain antibody phage display library was added and allowed to react at room temperature for one hour. The beads were washed nine times with PBST (0.05% Tween-20) solution to remove unbound phage. Phages that specifically bound to the truncated HSA were eluted with 1 mg / mL trypsin and infected with Escherichia coli TG1 in logarithmic phase growth to produce and purify phage for the next round of screening. After repeating the same screening process for 1-2 rounds, the positive clone sequences were enriched.
[0271] 4. Phage ELISA Identification
[0272] From the clones obtained in the last round of screening, monoclonal colonies were picked and packaged into phage single-chain antibodies for phage ELISA testing. The ELISA plates were coated with 2 μg / mL of human, monkey, and mouse serum albumin (HSA, CySA, mSA) overnight, blocked with 4% skim milk at 37°C for 1 hour, and then the phage supernatant blocked with 2% skim milk was added. The plates were allowed to react for 1 hour at room temperature, washed 3 times with PBST (0.05% Tween 20), and anti-M13 HRP was added for detection. The clones with OD450 values greater than 0.5 for the three albumins in the ELISA binding test were sequenced to obtain 50 specific sequences. Only some antibodies that showed high OD450 values for both human and monkey serum albumin were sequenced to obtain another 7 new specific sequences. 57 new specific sequences were obtained by phage screening.
[0273] Example 3. Construction of Antibody Mammalian Cell Expression Vector
[0274] The 57 specific sequences obtained by phage library screening in Example 2 were classified and organized, 19 of which were cloned, and the phage supernatant ELISA binding of these 19 anti-HSA antibodies was tested. The OD450 values of clones #7 and #9 are shown in Table 1.
[0275] Table 1. Anti-HSA antibody phage supernatant ELISA test results
[0276] >#7aHSA
[0277] >#9aHSA
[0278] In the above sequences SEQ ID NO: 6 and 7, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the FR sequences are in italics, and the CDR1, CDR2, and CDR3 sequences are underlined. The CDR sequences of the anti-HSA antibodies provided in the present disclosure are summarized in Table 2 according to the Kabat encoding.
[0279] Table 2. CDR sequences of anti-HSA antibodies (Kabat numbering rules)
[0280] Therefore, we provide the following CDRs for anti-HSA antibodies:
[0281] CDR1 is X1SCX2G, where X1 is T or N, and X2 is M or L;
[0282] CDR2 is X3IYX4VGGSTFYX5X6SVKG (SEQ ID NO: 58), wherein X3 is S or T, X4 is T or M, X5 is T or A, and X6 is N or D;
[0283] CDR3 is GSPARCX7X8RDPTTFX9Y (SEQ ID NO: 59), wherein X7 is R or L, X8 is L or R, and X9 is D or N.
[0284] The VHH sequence was fused to human IgG1-Fc (CH2-CH3) and constructed into the PTT5 expression vector. The sequence of the linked human IgG1-Fc is shown below:
[0285] >Human IgG1-Fc
[0286] The following is the full sequence of the VHH sequence fused to the human Fc (CH2-CH3) segment. The single underlined sequence is the human IgG1-Fc (CH2-CH3) segment sequence (shown in SEQ ID NO: 14), and the double underlined sequence is the linker sequence. The full sequence is as follows:
[0287] >#7aHSA-IgG1Fc:
[0288] >#9aHSA-IgG1Fc:
[0289] Example 4. Expression, screening and detection of anti-HSA antibodies
[0290] Human IgG1-Fc-fused anti-HSA antibodies #7aHSA and #9a were transiently expressed in HEK293 cells and affinity-purified with Protein A. Their activity was then assessed using ELISA binding assays and Biacore protein interaction assays.
[0291] The in vitro binding ability of #7aHSA and #9a anti-HSA antibodies to human, monkey, and mouse serum albumin was tested by ELISA binding assays using human serum albumin (Sigma, Cat No. 126658), monkey serum albumin (Abcam, Cat No. ab184894), and mouse serum albumin (Abcam, Cat No. ab183228). The negative control was PBS, and the positive control was ALB8 fused to human IgG1-Fc (the variable region sequence was derived from the ALB8 sequence in Ablynx patent publication WO 2008 / 028977 A2). The sequence is as follows:
[0292] >ALB8-IgG1-Fc
[0293] (Note: The single underline is the Fc region of IgG1, and the double underline is the linker region).
[0294] Human, monkey, and mouse albumin were diluted to 1 μg / mL using PBS buffer (pH 7.4) and added to a 96-well microtiter plate (Corning, Cat No. 9018) at a volume of 100 μL / well. The plate was incubated at 4°C overnight for 16-20 hours. After discarding the liquid, the plate was washed three times with PBST (pH 7.4, 0.05% Tween-20) buffer. A blocking solution of 2% skim milk powder diluted with PBS buffer was added (300 μL / well) and incubated at 37°C for 1 hour. After blocking, the blocking solution was discarded, and the plate was washed three times with PBST buffer. Anti-HSA antibody was added at an initial concentration of 2 μg / mL and diluted threefold in 11 steps using PBS buffer. The plate was incubated at 25°C for 1 hour. After the incubation, the reaction solution in the plate was discarded, the plate was washed three times with PBST, and 100 μL of HRP-labeled goat anti-human IgG Fc secondary antibody (Jackson immu, 109-035-190) (1:5000 dilution) was added to each well and incubated at 25°C for 1 hour. After washing the plate three times with PBST, 100 μL of TMB colorimetric substrate was added for color development. The reaction was terminated with 1 M sulfuric acid, and the absorbance value was read at OD450 nm using a SpectraMax M5 microplate reader. The absorbance value and antibody concentration were fitted using 4 parameters using GraphPad prism. The results are shown in Figures 1A-1C; the EC value of antibody binding to antigen was calculated. 50 The results are shown in Table 3.
[0295] Table 3. ELISA binding EC values of anti-HSA antibodies to human, monkey, and mouse albumin 50 (μg / mL) (Note: “ / ” indicates no binding was detected)
[0296] In addition, the affinity constants of anti-HSA antibodies fused to human IgG1 Fc for human, monkey, and mouse albumins (HSA, CySA, and mSA) were determined using a Biacore T200 (GE Healthcare) instrument. Protein A was first covalently coupled to a CM5 S series chip (GE, Cat. 29-1049-88) using an amino coupling kit (GE, Cat. BR-1000-50). The anti-HSA antibody was then affinity-captured onto the protein A-coupled chip. Different concentrations of human, monkey, and mouse albumin were then passed over the chip surface. The reaction signals were monitored in real time using a Biacore instrument to generate binding and dissociation curves. Affinity constants were obtained by fitting the curves to a Langmuir 1:1 binding model using BIAevaluation version 4.1, GE software. The buffer used in the experiment was HBS-EP solution (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH 7.4, GE, Cat.# BR-1006-69). After each cycle, the chip was regenerated using glycine-HCl (GE, Cat.# BR-1003-54) at pH 1.5. Affinity results are shown in Table 4.
[0297] Table 4. Affinity results of anti-HSA antibodies to human, monkey and mouse albumin
[0298] Example 5. Humanized transformation of anti-HSA antibodies
[0299] By performing three-dimensional homology modeling on the selected specific anti-HSA antibody molecule #7aHSA and comparing the results with the V-base human germline sequence database and the IMGT human antibody heavy chain variable region germline gene database, the highly homologous heavy chain variable region germline gene IGHV3-23 was selected as a template. The CDRs of the camelid single-domain antibody were transplanted into the corresponding human template, resulting in a variable region sequence with the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The transplanted single-domain antibody was subjected to further three-dimensional structural modeling and analysis. Specific sites within the FR region that affect CDR morphology were backmutated. The resulting modified antibody exhibits enhanced stability. Amino acid residues were assigned and annotated using the Kabat numbering system. The FRs of #7_Hu-9 and #7_Hu-10 retain more human germline sequences, resulting in less immunogenic mutations.
[0300] The design of back mutation sites and mutation methods are shown in Table 5.
[0301] Table 5. Back mutation sites and mutation patterns
[0302] The specific humanized sequences obtained are as follows, with the CDR regions underlined and the coding rules being the Kabat code:
[0303] >#7_Hu_1
[0304] >#7_Hu_2
[0305] >#7_Hu_3
[0306] >#7_Hu_4
[0307] >#7_Hu_5
[0308] >#7_Hu_6
[0309] >#7_Hu_7
[0310] >#7_Hu_8
[0311] >#7_Hu_9
[0312] >#7_Hu_10
[0313] The method described in Example 5 was used to construct a humanized anti-HSA antibody fusion protein with the Fc (CH2-CH3) region of hIgG1 or a protein fused with a 6His tag. The single underline indicates the hIgG1-Fc (CH2-CH3) region sequence (shown in SEQ ID NO: 14), the 6His tag sequence is in italics, and the linker sequence is in double underline. The protein sequences are as follows (using #7_hu_1-hIgG1Fc and #7_hu_10-6His as examples, and the same applies to other humanized anti-HSA antibodies). Regarding the antibody numbering convention, #7_hu_10-6His is the C-terminal fusion protein of #7_Hu_10 (SEQ ID NO: 26). The same is true for other antibodies.
[0314] >#7_hu_1-hIgG1Fc:
[0315] >#7_Hu_10-6His
[0316] >ALB8-6his
[0317] The plasmid was transiently transfected into HEK293 cells. After 5 days of cell culture, the expression supernatant was collected and centrifuged at 4000 rpm for 15 minutes to remove cells. The supernatant was harvested and filtered through a 0.45 μM filter. The supernatant was then purified using a Protein A column or a nickel column, or other conventional methods in the art, to obtain the anti-HSA antibody disclosed herein.
[0318] Example 6. Affinity determination of humanized anti-HSA antibodies with human, monkey, and mouse serum albumin
[0319] The affinity constants of a 6His-tagged humanized anti-HSA antibody for human, monkey, and mouse albumin were determined using a Biacore T200 (GE Healthcare) instrument. First, amino coupling was performed on a CM5 S series chip (GE, Cat. 29-1049-88) using an amino coupling kit (GE, Cat. BR-1000-50) and a His capture kit (GE, Cat. 28-9950-56) according to the kit instructions, achieving a surface response of approximately 10,000 RU. The chip was then blocked with ethanolamine and set aside for further use. The 6His-tagged humanized anti-HSA antibody was then affinity captured onto the anti-His chip. Different concentrations of human, monkey, and mouse albumin were then passed over the chip surface. The reaction signals were monitored in real time using the Biacore instrument to generate binding and dissociation curves. Affinity constants were obtained by fitting the curves to a Langmuir 1:1 binding model using BIAevaluation version 4.1, GE software. The buffer used in the experiment was HBS-EP solution (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH 7.4, GE, Cat.# BR-1006-69). After each cycle, the chip was regenerated using glycine-HCl (GE, Cat.# BR-1003-54, pH 1.5). The affinity results for some humanized antibodies are shown in Table 6. The results show that the affinity of the antibodies screened in the present disclosure for HSA is comparable to or slightly better than that of the positive control.
[0320] Table 6. Affinity of humanized anti-HSA antibodies to human, monkey, and mouse albumin
[0321] The anti-HSA antibody 7_Hu_10-6his was transiently expressed in HEK293E cells and purified via nickel column affinity chromatography. The affinity constants of the antibody to human, monkey, mouse, rat, dog, and rabbit albumins were determined using a Biacore T200 (GE Healthcare) instrument. First, amino coupling was performed on a CM5S series chip (GE, Cat. 29-1049-88) using an amino coupling kit (GE, Cat. BR-1000-50) and a His capture kit (GE, Cat. 28-9950-56) according to the kit instructions. The surface response value reached approximately 10,000 RU, and the chip was blocked with ethanolamine before use. A humanized anti-HSA antibody fused with a 6His tag was affinity captured onto the anti-His chip. Then, different concentrations of human, monkey, mouse, rat, dog, and rabbit albumin were passed over the chip surface. The reaction signals were detected in real time using a Biacore instrument to obtain binding and dissociation curves. Affinity constants were obtained by fitting the Langmuir 1:1 binding model using BIAevaluation version 4.1 and GE software. The buffer used in the experiment was HBS-EP solution (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH 7.4, GE, Cat.# BR-1006-69). After each cycle, the chip was regenerated using glycine-HCl (GE, Cat.# BR-1003-54), pH 1.5. Affinity results are shown in Table 7.
[0322] Table 7. Affinity of #7_Hu_10-6his to albumins from different species
[0323] Example 7. Effect of anti-HSA antibodies on the binding of FcRn and biotin-HSA in cells stably expressing hFcRn
[0324] The blocking effect of anti-HSA antibodies on the binding of HSA to FcRn was detected by measuring the fluorescence change of randomly biotinylated HSA bound to the surface of HEK293 cells stably expressing hFcRn mutants (293-hFcRn-mut cells). This experiment used HEK293 cells stably expressing hFcRn mutants (L320A, L321A), which are well localized and maintained on the cell membrane surface. Cells expressing hFcRn mutants were incubated with different concentrations of anti-HSA antibodies and biotin-HSA, followed by incubation with SA-FITC secondary antibody. The degree of reduction in the secondary antibody fluorescence signal (MFI) was used as a measure of the blocking effect of anti-HSA antibodies on the binding of biotin-HSA to FcRn. The specific experimental method is as follows:
[0325] After washing 293-hFcRn-mut cells twice with pH 5.5 PBS, 5 × 10 5 cells. After centrifugation and removal of the supernatant, 90 μL of anti-HSA antibody diluted in PBS (pH 5.5) and 10 μL of biotin-HSA (final concentration 250 μg / mL) were added to each well and incubated on ice for 40 minutes. After washing twice with 200 μL of PBS (pH 5.5), 100 μL of streptavidin-FITC secondary antibody (eBioscience, Cat No. 11-4317-87) diluted in PBS (pH 5.5) was added to each well at a dilution ratio of 1:200 and incubated on ice for 40 minutes. After washing twice with 200 μL of PBS (pH 5.5), 200 μL of PBS (pH 5.5) was added to each well. Fluorescence values were measured using a flow cytometer (BD Biosciences, BD Accuri C6) using the FL1 channel. Data were analyzed using FlowJo software, and the analysis results were plotted using Prism6 software. The inhibitory effect test results of some antibodies are shown in Figures 2A and 2B.
[0326] Result analysis: The fluorescence signal value (MFI) was used to determine whether the binding of anti-HSA antibody to HSA blocked the binding of HSA to FcRn. A decrease in the fluorescence signal indicated that the binding was blocked.
[0327] As shown in Figure 2A, the biotin-HSA + FcRn stably transfected cells + SA-FITC group (non-blocking group) served as a baseline; the biotin-HSA + HSA + FcRn stably transfected cells + SA-FITC group (HSA self-competing group) served as a positive control; Nc is an isotype control antibody. The results show that the anti-HSA antibodies #7_Hu_6-6his and #7_Hu_7-6his of the present disclosure do not block the binding of HSA to FcRn.
[0328] As shown in FIG2B , #7_Hu_10-6his and #7_Hu_10 did not block the binding of HSA to FcRn (tested at a concentration of 1 mg / mL).
[0329] This indicates that the anti-HSA antibody disclosed herein does not affect the pH-dependent binding of FcRn to HSA and can well maintain the FcRn-mediated serum albumin recycling mechanism.
[0330] Example 8. Pharmacokinetics of anti-HSA antibodies in mice
[0331] The pharmacokinetic characteristics of the anti-HSA antibodies of the present disclosure (#7_Hu_6-6his; #7_Hu_7-6his; #7_Hu_10-6his), a positive control antibody (ALB8-6his), and an isotype control antibody (isotype, a non-HSA-binding VHH molecule) were studied in CD-1 male mice (Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.). Three mice were administered via tail vein injection at a dose of 4 mg / kg on day 0. Blood samples were collected before administration and at 5 minutes, 1 hour, 7 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, and 144 hours after administration. Plasma was prepared using EDTA anticoagulation and centrifugation for pharmacokinetic analysis.
[0332] PK assay: 5 μg / mL anti-his antibody (Thermo, MAI-21315-1mg) was coated and added to a 96-well microtiter plate (Corning, Cat No. 9018) at a volume of 100 μL / well. The plate was placed at 4°C overnight for 16-20 hours. After discarding the liquid, the plate was washed three times with PBST (pH 7.4, 0.05% Tween-20) buffer. Casin Blocker (Thermo, 37528) blocking solution (300 μL / well) was added and incubated in a 37°C incubator for 2 hours for blocking. After blocking, the blocking solution was discarded, and the plate was washed three times with PBST buffer. Mouse plasma from different time points was added, appropriately diluted with diluent (Casin Blocker containing 1% CD1 mouse plasma), and incubated at 37°C for 1.5 hours. After incubation, the reaction solution was discarded from the plate, and the plate was washed three times with PBST. 100 μL of HRP-labeled rabbit anti-camelid cocktail VHH secondary antibody (Genescript, A02016, BSA-free) (1:5000 dilution) was added to each well and incubated at 37°C for 1 hour. After washing the plate three times with PBST, 100 μL of TMB chromogenic substrate was added for color development. The reaction was terminated with 1M sulfuric acid, and the absorbance was read at OD450nm using a SpectraMax M5 microplate reader. The VHH antibody concentration in the plasma sample was calculated based on the standard curve, and the results are shown in Figure 3. The calculated concentration was used to calculate the half-life using the PK solver, and the results are shown in Figure 4 and Table 8.
[0333] Table 8. Mouse plasma half-life of anti-HSA antibodies (Note: *, p < 0.05; **, p < 0.01; ***, p < 0.0001; ****, p < 0.00001; all compared with the positive control ALB8-6his)
[0334] The results showed that the anti-HSA antibodies #7_Hu_6-6his, #7_Hu_7-6his, and #7_Hu_10-6his disclosed herein had similar pK curves, half-lives within the half-life range of mouse serum albumin, and were superior to the positive control ALB8-6his antibody, and the clearance rates were also lower than that of the ALB8-6his antibody.
[0335] Example 9. Design and preparation of fusion protein
[0336] The relaxin A chain and B chain are connected by a linker to form a single-chain relaxin molecule. At the same time, in order to increase the half-life, the single-chain relaxin molecule is further fused with an anti-HSA single-domain antibody to form a fusion protein. The structural diagram is shown in Figure 5.
[0337] >Human RLN2 A chain
[0338] QLYSALANKCCHVGCTKRSLARFC (SEQ ID NO: 31)
[0339] >Human RLN2 B chain (delB1)
[0340] SWMEEVIKLCGRELVRAQIAICGMSTWS (SEQ ID NO: 32)
[0341] >Linker a
[0342] GGGGQGGGGQGGGGQGGGGQGGGGQ (SEQ ID NO: 33)
[0343] >Linker b
[0344] PGPAPGPAPGPAPGPAPGPAPGPAPGPAPGPA (SEQ ID NO: 34)
[0345] >Linker c
[0346] PGPQPGPQPGPQPGPQPGPQPGPQPGPQPGPQ (SEQ ID NO: 35)
[0347] >Linker d
[0348] GGGSGGSGGG (SEQ ID NO: 49)
[0349] >0051
[0350] >0052
[0351] >0053
[0352] >0062
[0353] >0063
[0354] >0064
[0355] >0065
[0356] >0066
[0357] Among them, italics are anti-HSA single-domain antibodies; single underlines are linkers 1; double underlines are linkers 2; bold is the B chain of relaxin 2; bold italics are the A chain of relaxin 2. Linker 1 can be selected from linkers a, b, and c, where a is a flexible linker and b and c are rigid linkers.
[0358] The positive control 0054 sequence of this example is from Example 7 of WO2021022139A1.
[0359] >0054
[0360] 1. Preparation of fusion protein:
[0361] The DNA sequences encoding the fusion proteins (SEQ ID NOs: 36-44) were codon-optimized, synthesized, and cloned into the pTT5 expression vector. The expression plasmids were transiently transfected into expiCHO (ThermoFisher, Cat. No. A29127) cells using the ExpiFectamine CHO Transfection Kit (ThermoFisher, Cat. No. A29133) according to the kit's instructions. The "High protocol" was used. The day after transfection, cells were cultured in suspension on a shaker at 32°C (5% CO2, 110 rpm, 75% humidity). Ten to 12 days after transfection, the cell culture supernatant was harvested, centrifuged at 4000 rpm for 20 minutes, and filtered through a 0.45 μM filter.
[0362] 2. Purification of fusion protein:
[0363] (1) Capture of fusion protein by A3 affinity chromatography: The supernatant of cell culture expressing the fusion protein was collected by high-speed centrifugation and filtered through a 0.22 μm filter. The A3 (JSR Life Sciences, Cat No. BP-AMS-A3-0100) affinity column was regenerated with 5 column volumes of 0.1 M NaOH (Sigma, Cat No. 71687) and then washed and equilibrated with 5 column volumes of 1× PBS (pH 7.4) (Sangon Biotech (Shanghai) Co., Ltd.: Cat No. E607016-0500). The filtered supernatant was loaded at a low flow rate to facilitate binding to the affinity column. The flow rate was controlled to maintain a retention time of approximately 1 min or longer. After binding, the column was rinsed with 5 column volumes of 1× PBS (pH 7.4), 5 column volumes of 1× PBS (pH 7.4) 0.8 M NaCl (Vetec, Cat No. V900058), and 5 column volumes of 1× PBS (pH 7.4) until UV absorbance returned to baseline. The sample was eluted with 0.1 M Glycine (pH 3.0) (Sigma, Cat No. 410225) buffer. The elution peak was collected for UV detection. The eluted product was quickly adjusted to pH 7-8 with 1 M Tris-HCl (pH 7.5) (Vetec, Cat No. V900483) and stored temporarily. For the eluted product, solution replacement can be performed using methods well known to those skilled in the art, such as ultrafiltration concentration using an ultrafiltration tube, and solution replacement to the desired buffer system, or replacement to the desired buffer system using molecular exclusion (such as G-25 desalting).
[0364] (2) Purification of fusion protein by hydrophobic chromatography: First, the sample was diluted with equal volumes of 20 mM Tris pH 7.5 (Vetec, Cat No. V900483) 1 M Na2SO4 (Sigma, Cat No. 239313) buffer. The Phenyl 650M (Toyopearl, Cat No. 0014478) hydrophobic chromatography column was regenerated with 5 column volumes of 0.5 M NaOH (Sigma, Cat No. 71687) and then washed and equilibrated with 10 column volumes of 20 mM Tris pH 7.5 (Vetec, Cat No. V900483) 0.5 M Na2SO4 (Sigma, Cat No. 239313). The diluted sample was loaded onto the hydrophobic column at a low flow rate to facilitate binding. The flow rate was controlled to maintain a retention time of approximately 2 minutes or longer. After binding, the column was flushed with 5 column volumes of 20 mM Tris pH 7.5 (Vetec, Cat. No. V900483) and 0.5 M Na2SO4 (Sigma, Cat. No. 239313) until UV absorbance returned to baseline. Elution was performed using a 0-100% gradient using 20 mM Tris pH 7.5 (Vetec, Cat. No. V900483) elution buffer. Purity was assessed by SEC-HPLC (TSKgel G3000SWXL, 5 μm, Cat. No. 008541) and the eluted peak was collected. The yield of the fusion protein after the two-step purification is shown in Table 9. The eluted product can be subjected to solution replacement using methods well known to those skilled in the art, such as ultrafiltration concentration using an ultrafiltration tube and solution replacement to the desired buffer system, or molecular exclusion (such as G-25 desalting) to replace the desired buffer system.
[0365] Table 9. Quality parameters of fusion proteins after two-step purification
[0366] After two-step purification, a complete and highly pure fusion protein was obtained, and the yield of the 0051 and 0053 molecules disclosed herein in transient transfection in expiCHO was twice that of the positive control molecule 0054 under the same conditions.
[0367] Example 10. Affinity determination of fusion protein with serum albumin from different species
[0368] The affinity of 0051 for human, monkey, rat, mouse, dog, porcine, rabbit, and bovine serum albumin was determined using a Biacore T200 (GE Healthcare) instrument. The positive control was 0054. Experiments were performed using human HSA (Sigma, Cat No. 126658), monkey albumin (Abcam, Cat No. ab184894), rat albumin (Abcam, Cat No. ab198656), mouse albumin (Abcam, Cat No. ab183228), rabbit albumin (Abcam, Cat No. ab188055), and bovine albumin (Sigma, Cat No. B2064).
[0369] 1. Affinity determination using anti-VHH antibody-coupled chips
[0370] Anti-VHH antibody (MonoRab) was coupled to S series CM5 sensor chip (GE, Cat No. 29-1049-88) using amino coupling kit (GE, Cat No. BR-1000-50). TM Rabbit Anti-Camelid VHH Cocktail (Genescript, Cat. No. A02014) was conjugated. The antibody was diluted to 10 μg / mL using 10 mM sodium acetate, pH 4.5 (GE, Cat. No. BR-1003-50). After EDC / NHS activation, the diluted anti-VHH antibody was passed through the CM5 chip to achieve a surface response of approximately 5000 RU. The chip was then blocked with ethanolamine and ready for use.
[0371] Albumins from various species were serially diluted in 1X HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Surfactant P20). The fusion proteins were captured using a conjugated anti-VHH antibody chip, achieving a response of approximately 30 RU. Serum albumin at varying concentrations was then passed over the chip for 3 minutes at a flow rate of 50 μL / min, with dissociation times ranging from 1 to 10 minutes (dissociation times varied depending on the albumin species). After each cycle, the chip was regenerated using 10 mM glycine-HCl, pH 1.5 (GE, Cat. No. BR-1003-54). Binding and dissociation curves were generated using a Biacore T200 (GE) system with real-time monitoring of the reaction signals. The data were fitted to a Langmuir 1:1 binding model using BIAevaluation version 4.1 software at appropriate concentrations to determine affinity values. The results are shown in Table 10.
[0372] Table 10. Affinity of fusion proteins to serum albumin from different species
[0373] The affinities of the different fusion proteins designed in the present disclosure to human, monkey, rat and bovine serum albumin were comparable to the positive control molecule 0054 (data not shown). Table 10 exemplifies the binding results to HSA and rat albumin.
[0374] 2. Affinity Determination Using Albumin-coupled Chips
[0375] Serum albumins of various species were conjugated to an S-series CM5 sensor chip (GE, Cat. 29-1049-88) using an amino coupling kit (GE, Cat. BR-1000-50). Each albumin species was diluted to 2 μg / mL. After EDC / NHS activation, the CM5 chip was passed through the diluted albumin to achieve a surface response of approximately 200 (180 to 230) RU, followed by blocking with ethanolamine. A blank control channel also required EDC / NHS activation and ethanolamine blocking.
[0376] Molecules 0051 and 0054 were serially diluted in 1X HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Surfactant P20): 2000, 666.66, 222.22, 74.074, 24.69, 8.23, 2.74, 0.91, and 0.305 nM. Samples of 0051 and 0054 at varying concentrations were passed through the albumin-coupled channel and the blank channel for 3 minutes at a flow rate of 50 μL / min and a dissociation time of 4 minutes. After each cycle, the chip was regenerated with 10 mM glycine-HCl, pH 1.5 (GE, Cat.# BR-1003-54). Biacore T200 (GE) was used to detect the reaction signal in real time to obtain the binding and dissociation curves. The obtained data were fitted with the Langmuir 1:1 binding model using BIAevaluation version 4.1 software at appropriate concentration points to obtain the affinity value.
[0377] Table 11. Affinity for albumins from different species
[0378] The affinity of molecule 0051 to human, monkey, and rat albumin is comparable to that of the positive control molecule 0054, but its affinity to mouse and canine albumin is weaker than that of the positive control molecule 0054 (data not shown). Table 11 shows the results for HSA, rat, and mouse.
[0379] Example 11. In vitro cell biological activity of fusion protein
[0380] 1. Biological activity of the fusion protein in THP-1 cells
[0381] THP-1 is a human peripheral blood mononuclear cell (Procell, Cat No. CL-0233) that endogenously expresses the RXFP1 receptor. Relaxin binds to the receptor on THP-1 cells, inducing THP-1 cells to produce cAMP. Therefore, this example measures the in vitro activity of the fusion protein by detecting the amount of cAMP produced. This example uses a homogeneous time-resolved fluorescence (HTRF) cAMP-Gs Dynamic kit (Cisbio, Cat No. 62AM4PEB) and measures cAMP levels based on the manufacturer's protocol. 0054, 800814 (derived from WO2015067113A1) and 0060 (WO2021255127A1, RELAX0023) were used as positive controls.
[0382] >800814's A chain
[0383] DLYSALANKCCHVGCTKRSLARFC (SEQ ID NO: 45)
[0384] >800814's B chain
[0385] DSWMEEVIKLCGRDLVRAQIAICGMSTWS (SEQ ID NO: 46)
[0386] >0060's A chain
[0387] >0060's B chain
[0388] The experimental method is as follows: THP-1 cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 0.05mM β-mercaptoethanol, 10% FBS, and 1% penicillin-streptomycin. On the day of the experiment, THP-1 cells in the logarithmic growth phase were harvested by centrifugation and resuspended in serum-free medium to adjust the cell density to 4×10 6Cells / mL were added and transferred to a 96-well assay plate (Cisbio, Cat No. 66PL96025) at a volume of 50 μL per well (20,000 cells / well). The fusion protein samples to be tested and the positive controls 0054, 0060, and 800814 were serially diluted 10-fold in a separate U-bottom 96-well plate using Stimulation Buffer 1 in the kit and transferred to a 96-well assay plate containing THP-1 cells at a volume of 5 μL per well. The cells were incubated at 37°C and 5% CO2 for 30 minutes. Cells without the test sample were used as a reference control. cAMP-d2 (acceptor fluorescent group) and anti-cAMP-cryptat (donor fluorescent group) were diluted using Lysis & Detection Buffer 1 in the kit, and cAMP-d2 was added to all wells of the 96-well assay plate except the blank control well at a volume of 5 μL per well. Anti-cAMP-cyptat was then added to all wells and incubated at room temperature for 1 hour in the dark. The readings were then taken on a Tecan (Infinite 200 PRO) at wavelengths of 620 nm and 665 nm. The signal intensity was expressed as the ratio of fluorescence intensity at 665 nm / fluorescence intensity at 620 nm × 10,000. Graphpad Prism was used for nonlinear fitting to plot the cAMP concentration curve, and the EC values of the test samples and controls for inducing cAMP production in THP-1 cells were obtained. 50 The results are shown in Table 12, Figures 6A and 6B.
[0389] Table 12. In vitro activity of fusion proteins (THP1 cell assay)
[0390] The results showed that the in vitro activities of the fusion proteins disclosed herein were comparable to those of the positive control molecule 0054.
[0391] 2. Biological activity of the fusion protein in CHO-K1 cells overexpressing RXFP receptor
[0392] (1) Preparation of CHO-K1 cells transiently transfected with RXFP1 and RXFP2 receptors
[0393] CHO-K1 cells (CCTCC, Cat No. GDC0018) were transiently transfected using Lipofectamine 2000 (Thermo Fisher, Cat No. 11668019). CHO-K1 cells were plated at 6 × 10 5The cells were resuspended in a 6-well plate at a concentration of 1.5 μg / well and cultured at 37°C, 5% CO2 for 12 hours. The original culture medium was removed and 1.5 mL of serum-free Ham's F-12K (Kaighn's) medium (Gibco, Cat No. 21127030) was added. For each well of cells: take two test tubes, test tube 1, dissolve 3 μg of corresponding plasmid DNA (human, dog, cynomolgus macaque, rat, mouse RXFP1 receptor or human RXFP2 receptor DNA plasmid) in 250 μL Opti-MEM I reduced serum medium (Gibco, Cat No. 31985070), test tube 2, dissolve 3 μL of Lipofectamine 2000 reagent in 250 μL Opti-MEM I reduced serum medium, incubate at room temperature for 5 minutes, then add the reagent in test tube 1 to test tube 2, mix gently, incubate at room temperature for 20 minutes, and add dropwise to a 6-well plate (500 μL / well). After 6 hours of transfection, change to complete medium and continue culturing for 24 hours before performing subsequent experiments.
[0394] (2) In vitro activation of fusion protein on its receptor
[0395] This example uses a homogeneous time-resolved fluorescence (HTRF) cAMP-Gs Dynamic kit (Cisbio, Cat No. 62AM4PEB) and measures cAMP levels based on the manufacturer's protocol. The specific method is as follows:
[0396] On the day of the experiment, CHO-K1 cells transfected with human, dog, cynomolgus monkey, rat, or mouse RXFP1 receptors were collected by centrifugation and resuspended in serum-free medium to adjust the cell density to 4 × 10 6Cells were plated at 50 μL per well (20,000 cells / mL) and transferred to a 96-well assay plate (Cisbio, Cat No. 66PL96025). Test sample 0051 and positive controls 0054, 0060, and 800814 were serially diluted 10-fold in a separate U-bottom 96-well plate using Stimulation Buffer 1 provided in the kit. The diluted samples were then transferred to a 96-well assay plate containing THP1 cells at a volume of 5 μL per well and incubated at 37°C, 5% CO₂ for 30 minutes. Cells without test sample addition served as a reference control. Use Lysis & Detection Buffer 1 in the kit to dilute cAMP-d2 (acceptor fluorescent group) and anti-cAMP-cryptat (donor fluorescent group), add cAMP-d2 to all wells of the 96-well assay plate except the blank control well at a volume of 5 μL per well, then add anti-cAMP-cyptat to all wells and incubate at room temperature for 1 hour in the dark. Then read the readings at 620nm and 665nm wavelengths on a Tecan (Infinite 200 PRO), and express the signal intensity as the ratio of fluorescence intensity at 665nm / fluorescence intensity at 620nm × 10,000. Graphpad Prism was used for nonlinear fitting to draw the cAMP concentration curve, and the EC value of cAMP production induced by the fusion protein and the control in CHO-K1 receptor-overexpressing cells was obtained. 50 The results are shown in Table 13 and Figure 6B.
[0397] Table 13. In vitro activity of fusion proteins (CHO-K1 receptor overexpressing cells)
[0398] The results showed that the in vitro activity of 0051 molecule was comparable to that of control molecules 0054 and 0060.
[0399] Example 12. Pharmacokinetics of fusion protein in rats
[0400] Male SD rats, 4-6 weeks old, weighing 200-250 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. During the feeding period, they had free access to food and water, a 12 / 12 hour light / dark cycle, a temperature of 16-26°C, and a relative humidity of 40-70%. After the animals arrived at the facility, they were adaptively fed for no less than 7 days. The day before the start of the experiment, the experimental animals were numbered and randomly divided into four groups, with 3 animals in each group. On the day of the experiment, the four groups of experimental animals were injected intravenously or subcutaneously with the test drugs 0051 and 0054, respectively. The dosage was 4 mg / kg, and the injection volume was 5 mL / kg.
[0401] For intravenous administration, blood was collected before dosing and at 0.5, 1, 3, 6, 24, 48, 72, 96, 120, 168, 192, and 240 hours after dosing. For subcutaneous administration, blood was collected before dosing and at 3, 6, 24, 48, 72, 96, 120, 168, 192, and 240 hours after dosing. 0.03 mL of whole blood was collected from each animal, anticoagulated with EDTA-K2, and immediately centrifuged at 4500 rpm for 5 minutes. The supernatant was placed in an EP tube and stored at -20°C. After the experiment, the supernatant was transferred to a -80°C tube.
[0402] Plasma concentrations of 0051 and 0054 were measured using an ELISA method: 100 μL / well of 96-well microtiter plates (Corning, Cat. No. 9018) were coated with 0.4 μg / mL Anti-Relaxin 2 / RLN2 antibody (Abcam, Cat. No. EPR21832-15) and incubated at 4°C overnight for 16-20 hours. After discarding the liquid, the plates were washed three times with PBST (pH 7.4, 0.05% Tween-20) buffer, followed by blocking with 300 μL / well of 4% bovine serum albumin solution and incubation at room temperature for 1 hour. Following blocking, the blocking solution was discarded, and the plates were washed three times with PBST buffer. Rat plasma from different time points was then added using a diluent: Casin Blocker (Thermo, Cat. No. 37528) containing 1% rat plasma. The plates were then incubated at 37°C for 1 hour. After incubation, the reaction solution was discarded from the plate, and the plate was washed three times with PBST. 100 μL of HRP-conjugated rabbit anti-camelid cocktail VHH secondary antibody (Genescript, Cat No. A02016, BSA-free) (1:5000 dilution) was added to each well and incubated at 37°C for 1 hour. After washing the plate three times with PBST, 100 μL of TMB (Sigma, Cat No. T0440) chromogenic substrate was added for color development. The reaction was terminated with 1 M sulfuric acid, and the absorbance was read at OD450 nm using a SpectraMax M5 microplate reader.
[0403] The data were analyzed using Graphpad Prism software. The concentrations of 0051 and 0054 molecules in plasma samples were calculated based on the standard curve. The results for rats are shown in Figure 7A. The calculated concentrations were used to calculate the half-life using a PK solver, and the results are shown in Table 14. In addition, we tested the pharmacokinetics of mice using a similar method. The results show that the AUC exposure and t of 0051 molecule were similar to those in Figure 7B. 1 / 2 Comparable to the positive control molecule 0054.
[0404] Table 14. Pharmacokinetic parameters in rats
[0405] PK results in rats showed that after IV administration, the AUC of 0054 was approximately twice that of 0051, with similar t1 / 2 differences between the two molecules. Following subcutaneous administration, the bioavailability of 0051 was higher than that of 0054. Compared with 0054, 0051 had a larger apparent volume of distribution (Vdss), indicating better tissue cell barrier permeability. Furthermore, 0051 had a longer apparent residence time (MRT), suggesting a longer duration of pharmacodynamic activity in vivo. Furthermore, after subcutaneous administration, the bioavailability (Bioavailability%) of 0051 was significantly higher than that of 0054. Therefore, 0051 possesses superior pharmacokinetic properties.
[0406] Example 13. Effect of fusion protein on myocardial hypertrophy in mice
[0407] A myocardial hypertrophy model was established in C57BL / 6J mice (Charles River Laboratories) by infusing isoproterenol (ISO, Sigma, Cat.#I5627) via subcutaneous implantation of a mini-osmotic pump (Alzet 1002). ISO was dissolved in PBS buffer (Servicebio, Cat.#G4202) containing 0.002% sodium ascorbate (Sigma, Cat.#11140) to a concentration of 146 mg / mL (calculated based on an average mouse weight of 25.8 g). The infusion concentration was 15 mg / kg / day. The pathological model was established by continuous infusion for 14 days. On the 14th day, the osmotic pump was removed, and the model control group 1 was euthanized and samples were collected. The remaining mice were randomly divided into groups and began to receive subcutaneous injections of fusion protein or control molecule. The dosage and grouping are shown in Table 15.
[0408] Table 15. Dosage and group information
[0409] At the end of the study, mice were fasted for 6 hours and weighed. The mice were euthanized and their heart weight and tibia length were measured. The ratio of heart weight to tibia length was used to assess cardiac hypertrophy, as shown in Figure 8 and Table 16.
[0410] Table 16. Heart weight and tibia length ratio in the mouse ISO cardiac hypertrophy model
[0411] The above measurement data are expressed as mean ± standard deviation (mean ± SD), and the two groups were compared using Student t test, *p < 0.05, **p < 0.01 vs. model control group 2; #p < 0.05 vs. blank control group.
[0412] ISO infusion can significantly induce myocardial hypertrophy in mice. Treatment with the fusion protein disclosed herein can reverse ISO-induced myocardial hypertrophy to baseline levels, with the required dose being significantly lower than that of the control 0060.
Claims
1. A fusion protein comprising a serum albumin binding domain and relaxin or an analog thereof, The serum albumin binding domain comprises an immunoglobulin single variable domain comprising a CDR1, a CDR2 and a CDR3 selected from any one of 1) to 3): 1) CDR1, CDR2 and CDR3 in the amino acid sequence of any one of SEQ ID NOs: 6, 18-27, 2) CDR1, CDR2 and CDR3 in the amino acid sequence shown in SEQ ID NO: 7, 3) CDR1, CDR2 and CDR3 having the amino acid sequences shown in SEQ ID NOs: 64, 58 and 59, respectively, in, The CDRs are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering systems; Preferably, the CDR1, CDR2 and CDR3 are shown as SEQ ID NOs: 8, 9 and 10, or as SEQ ID NOs: 11, 12 and 13, respectively.
2. The fusion protein of claim 1, wherein the immunoglobulin single variable domain is modified by any one of the following: camel origin or humanization, affinity maturation, removal of T cell epitopes, reduction of antibody deamidation, reduction of antibody aggregation, reduction of antibody isomerization, or a combination thereof; Preferably, the framework region template of the humanized human germline gene is derived from IGHV3-23.
3. The fusion protein of any one of claims 1 to 2, wherein the immunoglobulin single variable domain comprises an amino acid mutation at at least one of the following positions: 20, 23, 27, 29, 30, 37, 44, 45, 47, 49, 74, 78, 83, and 84; The stated positions are based on the EU numbering system; Preferably, it comprises at least one amino acid mutation selected from the group consisting of 20V, 23V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 49A, 74A, 78V, 83Q or 84P; More preferably, it comprises a combination of amino acid mutations selected from any one of the following: 27N, 29Y, 30L, 37F, 44E, 45R, 47G; 20V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G; 23V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 74A; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 78V; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 49A; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 83Q, 84P; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 84P; 30L, 37F, 44E, 45R, 47G, 84P; or 30L, 37F, 44E, 45R, 47G.
4. The fusion protein according to any one of the preceding claims, wherein the immunoglobulin single variable domain is: comprising an amino acid sequence as shown in any one of SEQ ID NOs: 6, 18-27, or having at least 90% sequence identity thereto, or The invention also comprises an amino acid sequence as shown in SEQ ID NO: 7 or an amino acid sequence having at least 90% sequence identity thereto.
5. The fusion protein according to any one of the preceding claims, wherein the immunoglobulin single variable domain is a VHH.
6. The fusion protein of any one of the preceding claims, wherein the relaxin or analog thereof comprises an A chain and a B chain, wherein the A chain has an amino acid sequence as set forth in any one of SEQ ID NOs: 31, 50, 52, 54, and 56, or an amino acid sequence having at least 90% sequence identity thereto, and the B chain has an amino acid sequence as set forth in any one of SEQ ID NOs: 32, 51, 53, 55, and 57, or an amino acid sequence having at least 90% sequence identity thereto; Preferably, the A chain and the B chain are selected from any combination of the following 1)-7): 1) Chain A shown in SEQ ID NO: 31 and Chain B shown in SEQ ID NO: 32; 2) Chain A shown in SEQ ID NO: 50 and Chain B shown in SEQ ID NO: 51; 3) Chain A shown in SEQ ID NO: 52 and Chain B shown in SEQ ID NO: 53; 4) Chain A shown in SEQ ID NO: 54 and Chain B shown in SEQ ID NO: 55; 5) Chain A shown in SEQ ID NO: 31 and Chain B shown in SEQ ID NO: 53; 6) Chain A shown in SEQ ID NO: 52 and Chain B shown in SEQ ID NO: 32; 7) Chain A shown in SEQ ID NO: 56 and chain B shown in SEQ ID NO:
57.
7. The fusion protein of claim 6, comprising a polypeptide as shown in any one of formulas (I) to (IV) or any combination thereof: B-L1-A-L2-VHH Formula (I) A-L1-B-L2-VHH Formula (II) VHH-L2-B-L1-A Formula (III) VHH-L1-A-L1-B Formula (III) in, A is the A chain of relaxin or an analog thereof, B is the B chain of relaxin or an analog thereof, L1 and L2 are linkers, L1 and L2 are each independently present or absent.
8. The fusion protein according to claim 7, wherein L1 comprises (GGGGQ)n, (GGGQ)n, (PGPQ)n, (PGPA)n, (G X S Y ) Z The amino acid sequence shown, wherein n is selected from an integer of 1-10, and X, Y, and Z are independently selected from integers of 1-10; L2 comprises a member selected from (G X S Y ) Z , KR, the amino acid sequence shown in any one of SEQ ID NOs: 60-63, 65-66, wherein X, Y, and Z are independently selected from integers of 1-10; Preferably, L1 comprises the amino acid sequence shown in any one of SEQ ID NOs: 33-35; Preferably, L2 comprises the amino acid sequence shown in SEQ ID NO:
49.
9. The fusion protein according to any one of the preceding claims, comprising an amino acid sequence as shown in any one of SEQ ID NOs: 36-43 or having at least 90% sequence identity thereto.
10. The fusion protein according to any one of the preceding claims, which is a single-chain protein, a dimer or a multimer protein.
11. A serum albumin binding molecule comprising an immunoglobulin single variable domain comprising a CDR1, a CDR2 and a CDR3 selected from any one of 1) to 3): 1) CDR1, CDR2 and CDR3 in the amino acid sequence of any one of SEQ ID NOs: 6, 18-27, 2) CDR1, CDR2 and CDR3 in the amino acid sequence shown in SEQ ID NO: 7, 3) CDR1, CDR2 and CDR3 having the amino acid sequences shown in SEQ ID NOs: 64, 58 and 59, respectively, in, The CDRs are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering systems; Preferably, the CDR1, CDR2 and CDR3 are shown as SEQ ID NOs: 8, 9 and 10, or as SEQ ID NOs: 11, 12 and 13, respectively.
12. The serum albumin binding molecule of claim 11, wherein the immunoglobulin single variable domain is modified by any one of the following: camel origin or humanization, affinity maturation, removal of T cell epitopes, reduction of antibody deamidation, reduction of antibody aggregation, reduction of antibody isomerization, or a combination thereof; Preferably, the framework region template of the humanized human germline gene is derived from IGHV3-23.
13. The serum albumin binding molecule of any one of claims 11-12, wherein the immunoglobulin single variable domain comprises an amino acid mutation at at least one of the following positions: 20, 23, 27, 29, 30, 37, 44, 45, 47, 49, 74, 78, 83, and 84; The stated positions are based on the EU numbering system; Preferably, it comprises at least one amino acid mutation selected from the group consisting of 20V, 23V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 49A, 74A, 78V, 83Q or 84P; More preferably, it comprises a combination of amino acid mutations selected from any one of the following: 27N, 29Y, 30L, 37F, 44E, 45R, 47G; 20V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G; 23V, 27N, 29Y, 30L, 37F, 44E, 45R, 47G; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 74A; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 78V; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 49A; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 83Q, 84P; 27N, 29Y, 30L, 37F, 44E, 45R, 47G, 84P; 30L, 37F, 44E, 45R, 47G, 84P; or 30L, 37F, 44E, 45R, 47G.
14. The serum albumin binding molecule according to any one of claims 11 to 13, wherein the immunoglobulin single variable domain is: comprising an amino acid sequence as shown in any one of SEQ ID NOs: 6, 18-27, or having at least 90% sequence identity thereto, or The invention also comprises an amino acid sequence as shown in SEQ ID NO: 7 or an amino acid sequence having at least 90% sequence identity thereto.
15. The serum albumin binding molecule according to any one of claims 11 to 14, wherein the immunoglobulin single variable domain is a VHH.
16. The serum albumin binding molecule according to any one of claims 11 to 15, further comprising a human immunoglobulin Fc region or a histidine tag; Preferably, the Fc region is the Fc region of human IgG1, IgG2, IgG3 or IgG4.
17. The serum albumin binding molecule of any one of claims 11 to 16, further comprising one or more therapeutic or diagnostic agents, Preferably, the therapeutic or diagnostic agent is covalently linked or fused to the immunoglobulin single variable domain; Preferably, the therapeutic agent or diagnostic agent is selected from any one of the following: a therapeutic or diagnostic protein, a polypeptide, a nucleic acid, or a small molecule compound.
18. The serum albumin binding molecule according to any one of claims 11 to 17, which has at least one activity selected from the group consisting of: (a) ≤1×10 -7 M, preferably ≤1×10 -8 M's K D Values bind to human serum albumin; (b) No blocking of serum albumin binding to FcRn was detected; (c) when comprising a therapeutic or diagnostic agent, extending the plasma half-life of the therapeutic or diagnostic agent.
19. A polynucleotide encoding the fusion protein according to any one of claims 1 to 10, or the serum albumin binding molecule according to any one of claims 11 to 18.
20. A vector comprising or expressing the polynucleotide of claim 19.
21. A host cell comprising or expressing the vector of claim 20.
22. A method for producing or preparing the fusion protein according to any one of claims 1 to 10 or the serum albumin binding molecule according to any one of claims 11 to 18, comprising the steps of: Cultivating the host cell of claim 22; recovering the fusion protein or serum albumin binding molecule, and Optionally, the fusion protein or serum albumin binding molecule is purified and / or modified.
23. A method for extending the plasma half-life of a therapeutic or diagnostic agent, comprising: The immunoglobulin single variable domain as defined in any one of claims 11 to 18 is linked or fused to the therapeutic or diagnostic agent.
24. A pharmaceutical composition comprising: The fusion protein of any one of claims 1 to 10, the serum albumin binding molecule of any one of claims 11 to 18, the polynucleotide of claim 19, or the vector of claim 20; Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents, buffers or excipients.
25. Use of the fusion protein according to any one of claims 1 to 10 in preparing a drug for treating or preventing a disease; Preferably, the disease is a fibrotic disease or a cardiovascular disease; More preferably, the cardiovascular disease is heart failure or myocardial hypertrophy.
26. Use of the serum albumin binding molecule according to any one of claims 11 to 18 in the preparation of a medicament for diagnosing, treating or preventing a disease.
